CURRICULUM VITAE

JATINDER K LAMBA, Ph.D

OFFICE ADDRESS

Associate Dean for Research and Graduate Education
Professor (with Tenure) | Frank A. Duckworth Eminent Scholar Chair
Department of Pharmacotherapy and Translational Research
College of Pharmacy,
Program Co-Leader: Cancer Targting and Therapeutics
UF Health Cancer Center
University of Florida
4332A, HPNP Building,
1225 Center Drive,
Gainesville, FL-32610
Phone: (352) 273 6425
Fax: (352) 273-6121
Email: jlamba@cop.ufl.edu
jatinderklamba@ufl.edu

IMMIGRATION STATUS US Citizen

ACADEMIC DEGREES

B.Sc. 1992 Panjab University, Chandigarh, India (Zoology, Botany, Chemistry)
M.Sc. 1994 Postgraduate Institute of Medical Education and Research, Chandigarh, India (Biochemistry, Department of Biochemistry)
Ph.D. 2000 Postgraduate Institute of Medical Education and Research, Chandigarh, India "Pharmacogenetics of CYP2C19 in North Indians".

PROFESSIONAL APPOINTMENTS

2000- 2006 Postdoctoral Research Associate, Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee
2006-2008 Research Associate Member, Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee
2008 –2011 Assistant Professor, Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota
2011-2014 Director, PUMA-Institute of Personalized Medicine, University of Minnesota, Minneapolis, Minnesota
2011-2014 Associate Professor with Tenure, Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota
2014-2019 Associate Professor with Tenure, Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida
2015- 2022 Graduate Program Director, Clinical Pharmaceutical Sciences Program, Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida
July 2019-Present Professor with Tenure, Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida
March 2023-Present Associate Dean for Research and Graduate Education, College of Pharmacy, University of Florida, Gainesville, Florida
Sep 2023- Present Program co-leader, UF Health Cancer Center, Cancer Targeting and Therapeutics Group.

Honors and Awards

1997 Indian Council of Medical Research, Senior Research Fellowship, New Delhi, India
1999 Silver Medal, Postgraduate Institute of Medical Education and Research, Chandigarh, India
1999 Servier Young Investigator Award, New Delhi, India
2009 Coauthored DMD manuscript (Association of breast cancer resistance protein/ABCG2 phenotypes with novel promoter and intron 1 single nucleotide polymorphisms" (Drug Metab Dispos 36(4):780-795, 2008) that received James R. Gillette Drug Metabolism Best Paper of 2008 award.
2009 Travel Award to participate in the International Association for Comparative Research on Leukemia and Related Diseases (IACRLRD) XXIV Symposium in Columbus, Ohio, October 2009.
2011-12 Chair-Elect - Pharmacogenomics Special Interest Group, American Association of Colleges of Pharmacy (AACP).
2012-13 Chair - Pharmacogenomics Special Interest Group, American Association of Colleges of Pharmacy (AACP).
2013-14 Vice-Chair - Pharmacogenomics Focus Group, American Association of Pharmaceutical Scientists (AAPS)
2014-15 Chair-Elect - Pharmacogenomics Focus Group, American Association of Pharmaceutical Scientists (AAPS)
2014-16 Chair - Pharmacogenomics Focus Group, American Association of Pharmaceutical Scientists (AAPS)
2014 American Society of Hematology Bridge Grant Awardee
2019-2021 University of Florida Term Professorship Award
2020-2023 University of Florida Research Foundation Professorship Award
2022-present Frank A. Duckworth Eminent Scholar chair

GRANTS
Funded: Active

1. NIH R01: 1R01 CA270120-01A1 12/15/2022-11/30/2027
   Project Title: Integrated Systems Biology of Pediatric AML
   Role: Principal Investigator
   Total Amount : $3,350,886
2. NIH**:** 2R01 CA132946 12A1 07/01/2021-06/30/2026
   Project Title: Genomics of AML prognosis
   Role: Principal Investigator
   Total Amount : $1,924,598
3. NIH U54
   Project Title: 2/3 Florida-California Cancer Research, Education & Engagement (CaRE2) Health Equity Center
   Role: Other
4. NIH R01DK129489
   Project Title: The role of ALKBH5-mediated RNA demethylation in the maintenance of genomic stability in HSPCs Health Equity Center
   Role: Co-Investigator
5. Hematology/Oncology Pharmacy Asso Foundation
   Project Title: Patterns of resistance to initial therapeutic treatment in Ewings Sarcoma

Role: co-Investigator

6. FL DEPT OF HLTH LIVE LIKE BELLA 04/2022- 03/2024
   Project Title Ultrasound elastogram assessment of liver fibrosis in children and adolescents/young adults (AYA) receiving chemotherapy or allogeneic bone marrow transplantation, and identification of risk factors for liver injury
   Role: Other
7. FL DEPT OF HLTH LIVE LIKE BELLA
   Project Title: Targeting ER Stress in Pediatric Acute Myeloid Leukemia
   Role: Co-I
8. Children's Hospital Orange County, California 1/2020-12/31/2023
   Role: Principal Investigator
   Title: Asparaginase Premedication, Hypersensitivity, and Therapeutic Drug Monitoring in Pediatric Patients with Acute Lymphoblastic Leukemia or Lymphoma
9. American Foundation for Pharm Edu
   Title: CRISPR Synthetic Lethality Screen Identifies Genomic Resistant/Sensitive Modulators of Standard Chemotherapy in Pediatric Acute Myeloid Leukemia (pAML)
   Role: Other

GRANTS
Funded: Completed

1. St Baldrick's Foundation/American Cancer Society 07/01/2021-12/31/2023
   Role: Principal Investigator
   Title: Transcriptomic and pharmacogenetic scores to guide therapy in pediatric AML
   Total: $235,000
2. Live Like Bella Foundation (Florida Department of Health) 04/2019-03/2022
   Project Title: Pharmacogenomics and Toxicities of Thiotepa, Busulfan and Fludarabine in Pediatric HSCT Recipients
   Role: Principal Investigator
   Amount: $223,759
3. Leukemia Lymphoma Society 07/2019-06/2022
   Project Title: Personalizing CD33-directed immunotherapy for pediatric AML
   Role: Principal Investigator
   Amount Total: $600000
4. NIH 2R01CA132946-06A1 09/01/2014-04/30/2019
   Role: Principal Investigator NCE-4/30/2020
   Title: Pharmacogenomics of Ara-C in AML
   Direct costs: $1,112,025
5. NIH: 1R01CA132946-01 (LAMBA) 4/2008 - 3/2014
   Role: Principal Investigator
   Title: Pharmacogenetics of Ara-C metabolic Pathway
   Direct costs: $ 1,740,406
6. UF COP Prosper Bridge Award 6/2020- 12/2021
   Role: Principal Investigator
   Title: Pharmacogenomics in AML
   Total: $40,000
7. Children's Oncology Group 06/2019-06/2020
   Role: Principal Investigator
   Title: Personalizing CD33-directed immunotherapy for pediatric AML.

Direct costs: $50,000 (Match to LLS grant)

8. NIH: 1R01CA132946-02S1
   Role: Principal Investigator
   Title: Pharmacogenetics of Ara-C metabolic Pathway; Recovery Act Administrative Supplement
   Direct costs: $ 92,000
9. NIH funded R21CA155524-01 (LAMBA) 4/2012 till 12/31/2015
   Role on Project: Principal Investigator
   Title: Impact of genetic variation on response to GO therapy in COG-AML clinical trials
   Direct costs: $275,000
10. PROSPER equipment award: University of Florida 2015-2016
    Role in Project: Principal Investigator
    Title: Purchase of Odyssey® CLx Infrared Imaging System
    Direct Costs: $20,000
11. AHC –Grant in Aid: Bridge funding (PI: Jatinder Lamba) Jan2014-Jun2014
    Role in Project: Principal Investigator I
    Title: Pharmacogenomics of ara-C in AML.
    Direct costs $ 30,000
12. American Society of hematology ASH-Bridge funding (PI: Jatinder Lamba) 2014
    Role in Project: Principal Investigator
    Title: Pharmacogenomics of ara-C in AML.
    Direct costs $ 100,000
13. AHC Developmental grant (PI: Van Ness) 2008-2012
    Role in Project: Co-PI
    Title: Genotype Associations with Disease Outcomes: Using Targeted SNP Genotyping to Assess Risk and Response in Lung Cancer.
    Direct costs $ 238,521
14. Minnesota Medical Foundation seed grant (PI: Van Ness) 2011-2012
    Role in the project: Co-PI
    Title: Generation of genetically diverse liver cultures from skin derived iPS libraries for population based drug screening.
    Direct costs: $10,000
15. Epilepsy foundation (Co-PI Birnbaum and Lamba) 2011-2013
    Role in Project: Co-PI
    Title: Pharmacokinetics and Pharmacogenetics of Epilepsy and Pregnancy
    Direct costs: $49,892
16. Children's Oncology Group 02/2018-02/2019
    Role on Project Principal Investigator
    Title: Impact of CD33 Genetics on Clinical Outcome in Pediatric AML patients treated on AAML0531 clinical trial.
    Direct costs: $50,000
17. PROSPER Faculty development award: University of Florida 2019-2020
    Role in Project: Principal Investigator
    Direct Costs: $5,000
18. UF Opportunity Funds 06/2018-05/2020; NCE:5/2021
    Role in the project: Principal Investigator
    Title: Development of Leukemia-Oncotype prototype CARS (Cytarabine AML Response Score (CARS) for prediction of relapse risk in AML
    Total cost: $85000

Grant Reviewer

- NIH Special Panel (ZGM1 PPBC -5) study section on "Integration of Pharmacogenomics with Electronic Health Records". Grant Reviewer (Jun 2009)
- Welcome Trust UK (2010-2011)
- Italian Ministry of Health (2012-2015)
- NIH Molecular and Cellular Hematology study Section (Adhoc reviewer, 2012)
- NIH Molecular and Cellular Hematology study Section (Adhoc reviewer June 2012)
- NIH Special Panel Epidemiology and Genetics of Cancer (July 2012)
- NIH Molecular and Cellular Hematology study Section (Adhoc reviewer, 2012)
- NIH ZRG1 DKUS C-04 Special Emphasis Panel (07/2014)
- NIH ZRG1 DKUS L-04 Special Emphasis Panel: Member Conflicts: Hepato-biliary Pathophysiology and Pharmacology (03/06/2015)
- NIH XNDA study section (Adhoc reviewer 10/2014, 02/2015 and 06/2015)
- NIH ZGM1PPBC Y-PG Special Emphasis panel (03/18-19/2015)
- NIH ZCA1 TCRB-T (J2) Collaborative Research in Integrative Cancer Biology (U01) 11/19/2015)
- NIH/NCI SPORE 1 ZCA1 RPRB-7 (M1) (02/03-4/2016)
- NIH/NIDDK GRB-JM1 (03/2016)
- **NIH XNDA study section-Standing member 2015-2019: 3 meetings every year in Feb, Jun and Oct.**
- NIH/NCI ZCA RPRB-7 (M1). NCI SPORE II Review (02/08-09/2017)
- NIH 2017/05 ZRG1 Genes, Genomes and Genetics (GGG)G-D (90) S-Genetics of Diseases (03/02/2017)
- NIH 2017/05 ZRG1 Genes, Genomes and Genetics (GGG)G-D (90) S-Genetics of Diseases (07/17/2017)
- Italian Ministry of Health 2016, 2017, 2018
- ISITE UNIVERSITE LILLE NORD-EUROPE. (2018)
- Alex Lemonade Stand crazy 8 initiative RFA brainstorming panel (2018)
- NCI Clinical and Translational R21and Omnibus R03. Special panel: (Nov 2018).
- NCI score grant reviews (Jan 2019)
- NCI special panel moonshot initiative: Novel Technology Tools to Facilitate Research Using Next Generation Patient-derived Cancer Models (U01s, 2019)
- NCI Application related to Pediatrics (Jan 2021)
- NCI 2021/10 ZRG1 F09A-R (20)L Fellowships: Oncology (July 2021, October 2021, March 2022, Nov 2022, March 2023)
- KiKa Foundation Oct 2021
- Medical Research Council Reviewer of Scientific fellowships – October 2021
- Royal society University of York grant reviewer January 2022
- Swiss National Science Foundation SNSF- Sep 2022, Nov 2022
- NCI 2023/10 ZCA1 SRB-K (O1) SEP-6: NCI Clinical and Translational Cancer Research
- NCI 2023/10 ZCA1 SRB-K (O1) SEP-5: NCI Clinical and Translational Cancer Research (R03/R21s), June 21-22, 2023, Feb 2024
- NCI 2023/08 ZRG1 CDPT-R (12) B: Small Business: The Cancer Biotherapeutics Development (CBD), July 17-18, 2023

Positions held in Professional Organizations and National/International Meetings

- Session co-chair: Gordon Research Conferences on Nucleosides, Nucleotides and Oligonucleotides (July 5-10, 2009), salve Regina University, Newport RI.
- Chair-Elect: Pharmacogenomics Special Interest Group, American Association of Colleges of Pharmacy, 2011-12
- Chair: Pharmacogenomics Special Interest Group, American Association of Colleges of Pharmacy, 2012-2013
- Session Chair: International Conference on Functional and Comparative Genomics & Pharmacogenomics, Track 6: Pharmacogenomics and Track 7: Genome Sequencing and Mapping. Chicago 2013
- Vice Chair: Pharmacogenomics Focus Group: American Association of Pharmaceutical Scientists (AAPS), 2013-2014.
- Chair-elect: Pharmacogenomics Focus Group: American Association of Pharmaceutical Scientists (AAPS), 2014-2015.
- Chair-elect: Pharmacogenomics Focus Group: American Association of Pharmaceutical Scientists (AAPS), 2014-2015.
- Chair: Pharmacogenomics Focus Group: American Association of Pharmaceutical Scientists (AAPS), 2015-2016.
- Session Chair: Genomics in Oncology. 21st International Symposium on Microsomes and Drug Oxidation, Davis, California, Oct 2-6 2016
- Conference Organizer and Session Chair: Genomics and Pharmacogenomics, 2017 London
- Scientific Program Committee Member PGRN 2021—present
- Session Co-Chair: PGRN Global meeting Jun 11-13, 2023
- Session co-chair: Purine and Pyrimidine Society Bi Annual Symposium: June 26-29 2023
- Session Moderator: American Society of Hematology ASH, Dec 2022

Editorial/Review Board Member

Pharmacogenomics
Frontiers in Pharmacogenetics and genomics
Leukemia and lymphoma
Journal of Cellular and Molecular Medicine
Cancers
Cancers (Editor special issue - Women's Special Issue Series: Oncology) 2022-2023

Ad Hoc Journal Article Reviewer

Drug Metabolism and Disposition
Journal of Pharmacology and Experimental Therapeutics
Biochemical Pharmacology
American Journal of Hematology
Pharmacogenetics and genomics
Pharmacogenomics
Clinical Cancer Research
Human Genetics
Leukemia and Lymphoma
Journal of Cellular and Molecular Medicine

Cancer Treatment Reviews
Oncotarget
Clinical Cancer Research
Scientific Reports
Blood
Future Oncology
Journal of Cellular and Molecular Medicine
Hematologica

PATENT submissions

Title	Status	Application No
Pharmacogenomics score to make decisions on therapy augmentation in AML	Filed	US Provisional Application No.: 63/233,673
Methods for Predicting AML Outcome	Published	PCT/US2020/051961
Development of Novel CD33 Antibodies	Filed	63/078,686
CD33-Targeted Cancer Therapy	Nationalized	PCT/US2017/026369

PUBLICATIONS

Online news or articles
Some recent new articles highlighting our results from CD33 and Gemtuzumab therapy published article in Journal of Clinical Oncology (2017, 2019):

- HTTP://PHARMACY.UFL.EDU/2017/06/19/UF-RESEARCHERS-IDENTIFY-GENE-VARIANT-TO-PERSONALIZE-THERAPY-FOR-DEADLY-FORM-OF-LEUKEMIA/
- HTTPS://WWW.FREDHUTCH.ORG/EN/NEWS/CENTER-NEWS/2017/06/MYLOTARG-PRECISION-MEDICINE.HTML
- HTTP://WWW.THELANCET.COM/JOURNALS/LANONC/ARTICLE/PIIS1470-2045(17)30507-7/FULLTEXT
- HTTP://WWW.ONCOTHERAPYNETWORK.COM/LEUKEMIA-LYMPHOMA/ANTI-LEUKEMIC-DRUG-GEMTUZUMAB-OZOGAMICIN-MAY-BENEFIT-SOME-AML-PATIENTS
- HTTP://WWW.HEMATOLOGY.ORG/THEHEMATOLOGIST/DIFFUSION/7883.ASPX
- HTTP://WWW.ASCOPOST.COM/NEWS/57834
- HTTPS://PTR.PHARMACY.UFL.EDU/2019/05/01/DR-JATINDER-LAMBA-RECEIVES-200000-GRANT-TO-STUDY-PEDIATRIC-CANCER/
- HTTPS://PTR.PHARMACY.UFL.EDU/2019/08/05/LEUKEMIA-AND-LYMPHOMA-SOCIETY-AWARDS-GRANT-TO-SUPPORT-PEDIATRIC-CANCER-RESEARCH/

OTHER NEWS ARTICLES

- HTTP://POST.HEALTH.UFL.EDU/2015/05/27/THE-PROMISE-OF-BETTER-THERAPY/
- https://ufhealth.org/news/2015/tailor-cancer-treatment-study-uses-computer-simulation-model-patient-cancer-dna
- http://gatorx.pharmacy.ufl.edu/files/2017/10/Gatorx2015.pdf

2022:Media news on JCO article reporting Polygenic score that can help personalize AML chemotherapy

- https://ufhealth.org/news/2022/uf-researchers-develop-genetic-score-improve-pediatric-cancer-treatments
- https://pharmacy.ufl.edu/2022/01/14/uf-researchers-develop-genetic-score-to-improve-pediatric-cancer-treatments/

- https://innovate.research.ufl.edu/2022/01/14/uf-personalized-pediatric-leukemia-chemotherapy/?utm_source=rss&utm_medium=rss&utm_campaign=uf-personalized-pediatric-leukemia-chemotherapy
- https://www.wcjb.com/2022/01/15/new-study-allows-uf-health-researchers-customize-treatments-children-with-cancer/
- https://www.mainstreetdailynews.com/health/uf-researchers-develop-improved-cancer-medicine/article_371e4350-7752-11ec-9ee6-e72e59a65607.html
- https://www.orlandomedicalnews.com/article/5363/uf-researchers-develop-genetic-score-to-improve-pediatric-cancer-treatments
- https://www.alachuatoday.com/news-featured/latest/4987-uf-researchers-develop-genetic-score-to-improve-pediatric-cancer-treatments
- https://www.precisiononcologynews.com/cancer/polygenic-scoring-shows-promise-guiding-induction-chemo-pediatric-aml-early-research?_ga=2.134480497.1489605912.1642730041-799510000.1642730041&adobe_mc=MCMID=66393348726035109261370227483714298097|MCORGID=138FFF2554E6E7220A4C98C6%40AdobeOrg|TS=1642730054&CSAuthResp=1::2014115:1911:24:success:F88009C6C3C324B78DB6DF221B878778#.YeoSVC2ZPVo
- https://consumer.healthday.com/polygenic-score-can-personalize-aml-treatment-2656438922.html
- https://ascopost.com/news/february-2022/use-of-polygenic-cytarabine-response-score-to-identify-candidates-with-pediatric-aml-for-chemotherapy-augmentation/
- https://www.cancertherapyadvisor.com/home/cancer-topics/hematologic-cancers/acute-leukemia-aml-polygenic-score-identify-kids-young-adults/
- https://www.drugs.com/news/polygenic-score-helps-guide-choice-chemo-pediatric-aml-103249.html
- https://www.news-herald.net/lifestyles/health/polygenic-score-helps-guide-choice-of-chemo-for-pediatric-aml/article_5d79f3e6-fbab-5687-8272-1a5b02b6453a.html
- https://www.researchgate.net/publication/357647615_Polygenic_Ara-C_Response_Score_Identifies_Pediatric_Patients_With_Acute_Myeloid_Leukemia_in_Need_of_Chemotherapy_Augmentation
- https://www.wyomingnews.com/lifestyles/health/polygenic-score-helps-guide-choice-of-chemo-for-pediatric-aml/article_86dac3cc-03d5-5edf-ae5f-005db05b72b0.html
- https://www.caledonianrecord.com/features/health/polygenic-score-helps-guide-choice-of-chemo-for-pediatric-aml/article_e2d751ba-ab63-5edc-9a14-7c6856ec09cb.html
- https://alternativechannel.tv/polygenic-score-helps-guide-choice-of-chemotherapy-for-pediatric-aml-health-and-fitness/
- https://www.seacoastecho.com/lifestyles/health/polygenic-score-helps-guide-choice-of-chemo-for-pediatric-aml/article_e4fcf2f5-9ca6-5115-9fb7-bebd898cc0b5.html?mode=comments
- https://www.prep4gold.org/post/uf-researchers-develop-genetic-score-to-improve-pediatric-cancer-treatments

2023: Media coverage article pubished in Journal of Clincial Oncology- Precision Oncology

- Miami TV coverage: https://www.local10.com/health/2023/05/09/discovery-may-improve-treatment-for-some-leukemia-patients/
- https://ufhealth.org/news/2023/uf-researchers-create-method-predict-leukemia-drug-complications
- https://healthitanalytics.com/news/ai-prediction-tool-identifies-chemotherapy-drug-toxicity-risk

Online publications:

1. Title: ***Paths to Precise Prescriptions***) was highlighted in *International Innovations* Journal. https://cop-main.sites.medinfo.ufl.edu/files/2014/08/Paths-to-Precise-Prescriptions.pdf)
2. Title: The genetic Puzzle: why do we respond to cancer therapy? http://www.scientiapublications.com/jatinder-lamba-science-diffusion/
3. Title: Personalising antibody directed therapy in Acute Myeloid Leukaemia (AML) (Nov.2017) https://www.openaccessgovernment.org/personalising-antibody-directed-therapy-acute-myeloid-leukaemia/39415/

4. Title: Acute Myeloid Leukemia and cytarabine pharmacogenomics (Feb 2, 2018) https://www.openaccessgovernment.org/acute-myeloid-leukaemia-aml-cytarabine-pharmacogenomics/42053/
5. Title: Acute Myeloid Leukemia AML research and Application (April, 20, 2018) https://www.openaccessgovernment.org/acute-myeloid-leukaemia-aml-research-and-application/44874/
6. Title: CD33 directed therapy: Current and future perspective in acute myeloid leukemia (AML) (Sep 2018) https://www.openaccessgovernment.org/cd33-directed-therapy/47313/
7. *EMJ Hematology US Edition*. (2020) https://www.emjreviews.com/hematology/journal/emj-hematology-us-1-1-2020/

American Society of Hematology Dec 2023, Press coverage
https://www.hematology.org/newsroom/annual-meeting-press/annual-meeting-press-programlamba
and race
https://cancer.ufl.edu/2023/12/09/using-patients-genetic-profile-to-inform-aml-treatment-could-help-reduce-racial-disparities/
https://ascopost.com/news/december-2023/acs10-score-may-help-inform-treatment-reduce-racial-disparities-in-black-pediatric-patients-with-aml/
https://www.healio.com/news/hematology-oncology/20231209/using-pharmacogenomics-to-guide-induction-may-reduce-racial-disparities-in-pediatric-aml
https://www.medscape.com/viewarticle/this-test-may-guide-aml-therapy-black-pediatric-patients-2023a1000usg
https://www.precisionmedicineonline.com/precision-oncology/polygenic-score-may-help-personalize-induction-chemo-improve-black-pediatric-aml

Peer Reviewed Research publications:

1. Shastri VM, Chauhan L, Gbadamosi M, Alonzo TA, Wang YC, Aplenc R, Hirsch BA, Kolb EA, Gamis AS, Meshinchi S, Lamba JK.Genetic variation in DNA damage response pathway and response to Gemtuzumab Ozogamicin in pediatric AML: a report from the Children's Oncology Group.Clin Cancer Res. 2024 Jan 10. doi: 10.1158/1078-0432.CCR-23-2073. PMID: 38197878
2. Seligson ND, Kolesar JM, Alam B, Baker L, **Lamba JK**, Fridley BL, Salahudeen AA, Hertz DL, Hicks JK. Integrating pharmacogenomic testing into paired germline and somatic genomic testing in patients with cancer. Pharmacogenomics. 2023 Aug;24(13):731-738. doi: 10.2217/pgs-2023-0125. PMID: 37702060
3. Thomas M, Li J, King K, Persaud AK, Duah E, Vangundy Z, Hofmeister CC, **Lamba JK,** Tan AC, Fridley BL, Poi MJ, Seligson ND. PARP1 and POLD2 as prognostic biomarkers for multiple myeloma in autologous stem cell transplant. Haematologica. 2023 Aug 1;108(8):2155-2166. doi: 10.3324/haematol.2022.282399.PMID: 36861411
4. Marrero RJ, **Lamba JK**. Current Landscape of Genome-Wide Association Studies in Acute Myeloid Leukemia: A Review.Cancers (Basel). 2023 Jul 12;15(14):3583. doi: 10.3390/cancers15143583.PMID: 37509244 Free PMC article.
5. Fraser A, Castillo P, Cascio E, Moore-Higgs G, Farhadfar N, Fort J, Slayton W, **Lamba J**, Horn B Feasibility study of busulfan, fludarabine, and thiotepa conditioning regimen for allogeneic hematopoietic stemcell transplantationfor children and young adults with nonmalignant disorders. Pediatr Blood Cancer. 2023 Jul;70(7)
6. Larkin T, Kashif R, Elsayed AH, Greer B, Mangrola K, Raffiee R, Nguyen N, Shastri V, Horn B, **Lamba JK** Polygenic Pharmacogenomic Markers as Predictors of Toxicity Phenotypes in the Treatment of Acute Lymphoblastic Leukemia: A Single-Center Study. JCO Precis Oncol. 2023 Mar;7:e2200580.

7. Thomas M, Li J, King K, Persaud AK, Duah E, Vangundy Z, Hofmeister CC, **Lamba JK**, Tan AC, Fridley BL, Poi MJ, Seligson ND. PARP1 and POLD2 as prognostic biomarkers for multiple myeloma in autologous stem cell transplant. Haematologica, 2023
8. Marrero RJ, Cao X, Wu H, Elsayed AH, Klco JM, Ribeiro RC, Rubnitz JE, Ma X, Meshinchi S, Aplenc R, Kolb EA, Ries RE, Alonzo T, Pounds SB, **Lamba JK.** SAMHD1 Single Nucleotide Polymorphisms Impact Outcome in Children with Newly Diagnosed Acute Myeloid Leukemia. Blood Adv, 2023
9. Brooks JT, Solans BP, Lu Y, Kharbanda S, Dvorak CC, Lalefar N, Long S, Gupta AO, Horn B, **Lamba JK**, Huang L, Apsel-Winger B, Keizer RJ, Savic R, Long-Boyle J. Prospective Validation and Refinement of a Population Pharmacokinetic Model of Fludarabine in Children and Young Adults Undergoing Hematopoietic Cell Transplantation. Pharmaceutics 14, 2022
10. Lim JE, Sargur Madabushi S, Vishwasrao P, Song JY, Abdelhamid AMH, Ghimire H, Vanishree VL, **Lamba JK**, Dandapani S, Salhotra A, Lemecha M, Pierini A, Zhao D, Storme G, Holtan S, Aristei C, Schaue D, Al Malki M, Hui SK.Total marrow irradiation reduces organ damage and enhances tissue repair with the potential to increase the targeted dose of bone marrow in both young and old mice. Front Oncol 12:1045016, 2022
11. **Lamba JK**, Pounds S: Proteomics: a new era in pediatric acute myeloid leukemia research. Haematologica 107:2288-2289, 2022
12. Nguyen NH, Rafiee R, Tagmount A, Sobh A, Loguinov A, de Jesus Sosa AK, Elsayed AH, Gbadamosi MO, Seligson ND, Cogle CR, Rubnitz JE, Ribeiro RC, Downing JR, Cao X, Pounds SB, Vulpe CD, **Lamba JK.** Genome-wide CRISPR/Cas9 Screen Identifies Etoposide Response Modulators Associated with Outcomes in Pediatric AML. Blood Adv, 2023
13. Gbadamosi MO, Shastri VM, Elsayed AH, Ries R, Olabige O, Nguyen NHK, De Jesus A, Wang YC, Dang A, Hirsch BA, Alonzo TA, Gamis A, Meshinchi S, **Lamba JK.** A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials. **Leukemia.** 2022. PMID: 35688939
14. **Elsayed AH, Cao X, Mitra AK, Wu H, Raimondi S, Cogle C, Al-Mansour Z, Ribeiro RC, Gamis A, Kolb EA, Aplenc R, Alonzo TA, Meshinchi S, Rubnitz J, Pounds S, Lamba JK. Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation. J Clin Oncol. 2022 PMID: 34990262**

*** Commentary in J Clin Oncol. 2022. PMID: 35025625 Jordheim LP. Toward Personalization of Cytarabine Dosing in Acute Myeloid Leukemia.

15. Lamba JK, Pounds S. Proteomics: a new era in pediatric acute myeloid leukemia research. Haematologica. 2022 Jan 13. doi: 10.3324/haematol.2021.280305. Online ahead of print.PMID: 35021610
16. Fornerod M, Ma J, Noort S, Liu Y, Walsh MP, Shi L, Nance S, Liu Y, Wang Y, Song G, Lamprecht T, Easton J, Mulder HL, Yergeau D, Myers J, Kamens JL, Obeng EA, Pigazzi M, Jarosova M, Kelaidi C, Polychronopoulou S, **Lamba JK**, Baker SD, Rubnitz JE, Reinhardt D, van den Heuvel-Eibrink MM, Locatelli F, Hasle H, Klco JM, Downing JR, Zhang J, Pounds S, Zwaan CM, Gruber TA; Berlin-Frankfurt-Munster Study Group (BFM); Dutch Children's Oncology Group (DCOG); Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP); Nordic Society for Pediatric Hematology and Oncology (NOPHO); Dutch Children's Oncology Group (DCOG); for St. Jude Children's Research Hospital Study Group (SJCRH). Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators. Blood Cancer Discov. 2021 Sep 9;2(6):586-599. doi: 10.1158/2643-3230.BCD-21-0049. eCollection 2021 Nov.PMID: 34778799
17. Yang G, Singh S, McDonough CW, **Lamba JK**, Hamadeh I, Holliday LS, Wang D, Katz J, Lakatos PA, Balla B, Kosa JP, Pelliccioni GA, Price DK, Van Driest SL, Figg WD, Langaee T, Moreb JS, Gong Y. Genome-wide Association Study Identified Chromosome 8 Locus Associated with Medication-Related Osteonecrosis of the Jaw. Clin Pharmacol Ther. 2021 Dec;110(6):1558-1569.

doi: 10.1002/cpt.2397. Epub 2021 Aug 31.PMID: 34390503
18. Nguyen NHK, Wu H, Tan H, Peng J, Rubnitz JE, Cao X, Pounds S, **Lamba JK**. Global Proteomic Profiling of Pediatric AML: A Pilot Study. Cancers (Basel). 2021 Jun 24;13(13):3161.PMID: 34202615
19. **Lamba JK,** Meshinchi S. Time to reconsider CD33 SNP for gemtuzumab response. Haematologica. 2021 May 27. doi: 10.3324/haematol.2021.279043. PMID: 34092060
20. Stockard B, Bhise N, Shin M, Guingab-Cagmat J, Garrett TJ, Pounds S, **Lamba JK**. Cellular Metabolomics Profiles Associated With Drug Chemosensitivity in AML. Front Oncol. 2021 Jun 10;11:678008. doi: 10.3389/fonc.2021.678008.PMID: 34178663**.**
21. Chamala S, Maness HTD, Brown L, Adams CB, **Lamba JK**, Cogle CR. Building a precision oncology workforce by multidisciplinary and case-based learning. BMC Med Educ. 2021 Jan 26;21(1):75. doi: 10.1186/s12909-021-02500-6.PMID: 33499867.
22. Gbadamosi MO, Shastri VM, Hylkema T, Papageorgiou I, Pardo L, Cogle CR, Doty A, Loken MR, Meshinchi S, **Lamba JK**. Novel CD33 antibodies unravel localization, biology and therapeutic implications of CD33 isoforms. Future Oncol. 2021 Jan;17(3):263-277. PMID: 33356566.
23. Zhou Y, Takacs GP, **Lamba JK**, Vulpe C, Cogle CR. Functional Dependency Analysis Identifies Potential Druggable Targets in Acute Myeloid Leukemia. Cancers (Basel). 2020 Dec 10;12(12):3710. PMID: 33321907; PMCID: PMC7764352.
24. **Lamba JK,** Cao X, Raimondi S, Downing J, Ribeiro R, Gruber TA, Rubnitz J, Pounds S. DNA Methylation Clusters and Their Relation to Cytogenetic Features in Pediatric AML. Cancers (Basel). 2020 Oct 17;12(10):3024. doi: 10.3390/cancers12103024. PMID: 33080932; PMCID: PMC7603219.
25. Yang G, Collins JM, Rafiee R, Singh S, Langaee T, McDonough CW, Holliday LS, Wang D, **Lamba JK**, Kim YS, Pelliccioni GA, Vaszilko M, Kosa JP, Balla B, Lakatos PA, Katz J, Moreb J, Gong Y. SIRT1 Gene SNP rs932658 Is Associated With Medication-Related Osteonecrosis of the Jaw. J Bone Miner Res. 2020. PMID: 32967053.
26. Buelow DR, Anderson JT, Pounds SB, Shi L, **Lamba JK**, Hu S, Gibson AA, Goodwin EA, Sparreboom A, Baker SD. DNA Methylation-Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia. Clin Transl Sci. 2020 Sep 9. doi: 10.1111/cts.12861. PMID: 32905646.
27. Yu J, Black V, **Lamba J**, Horn B. Potential Risk Factors Associated With Graft Failure of Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) in Children With Sickle Cell Disease (SCD). J Pediatr Hematol Oncol. 2020 Jun 26. doi: 10.1097/MPH.0000000000001873. Epub ahead of print. PMID: 32604335.
28. Short NJ, Richard-Carpentier G, Kanagal-Shamanna R, Patel K, Konopleva M, Papageorgiou I, Pemmaraju N, Borthakur G, Ravandi F, DiNardo CD, Kadia TM, Kantarjian H, **Lamba JK**, Daver N. Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin. Am J Hematol. 2020 PMID: 32356320.
29. Mitra-Ghosh T, Callisto SP, **Lamba JK**, Remmel RP, Birnbaum AK, Barbarino JM, Klein TE, Altman RB. PharmGKB summary: lamotrigine pathway, pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2020 Jun;30(4):81-90. PMID: 32187155.
30. Elsayed AH, Rafiee R, Cao X, Raimondi S, Downing JR, Ribeiro R, Fan Y, Gruber TA, Baker S, Klco J, Rubnitz JE, Pounds S, **Lamba JK**. A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia. Leukemia. 2019 Oct 23. PMID:31645648.

31. Drusbosky LM, Singh NK, Hawkins KE, Salan C, Turcotte M, Wise EA, Meacham A, Vijay V, Anderson GG, Kim CC, Radhakrishnan S, Ullal Y, Talawdekar A, Sikora H, Nair P, Khanna-Gupta A, Abbasi T, Vali S, Guha S, Farhadfar N, Murthy HS, Horn BN, Leather HL, Castillo P, Tucker C,

Cline C, Pettiford L, **Lamba JK,** Moreb JS, Brown RA, Norkin M, Hiemenz JW, Hsu JW, Slayton WB, Wingard JR, Cogle CR. A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients. Blood Adv. 2019 Jun 25;3(12):1837-1847. PMID: 31208955.

32. Chauhan L, Shin M, Wang YC, Loken MR, Pollard J, Aplenc R, Hirsch BA, Raimondi S, Ries R, Bernstein ID, Gamis AS, Alonzo TA, Meshinchi S, **Lamba JK.** CD33_PGx6_Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: A report from the Children's Oncology Group. JCO Precision Oncology 2019 :3, 1-15
33. Rafiee R, Chauhan L, Alonzo TA, Wang YC, Elmasry A, Loken MR, Pollard J, Aplenc R, Raimondi S, Hirsch BA, Bernstein ID, Gamis AS, Meshinchi S, **Lamba JK**. ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 Trial. Blood Cancer J. 2019 May 21;9(6):51. PubMed PMID: 31113932.
34. Bhise NS, Elsayed AH, Cao X, Pounds S, **Lamba JK**. MicroRNAs Mediated Regulation of Expression of Nucleoside Analog Pathway Genes in Acute Myeloid Leukemia. Genes (Basel). 2019 Apr 24;10(4).PubMed PMID:31022985.
35. Yang G, Singh S, Chen Y, Hamadeh IS, Langaee T, McDonough CW, Holliday LS,**Lamba J**, Moreb JS, Katz J, Gong Y. Pharmacogenomics of osteonecrosis of the jaw. Bone. 2019 Apr 22.PubMed PMID: 31022475.
36. Lin KH, Xie A, Rutter JC, Ahn YR, Lloyd-Cowden JM, Nichols AG, Soderquist RS, Koves TR, Muoio DM, MacIver NJ, **Lamba JK**, Pardee TS, McCall CM, Rizzieri DA, Wood KC. Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity. Cell Metab. 2019 Feb 5. PubMed PMID: 30773463.
37. Papageorgiou I, Loken MR, Brodersen LE, Gbadamosi M, Uy GL, Meshinchi S, **Lamba JK**. CCGG deletion (rs201074739) in CD33 results in premature termination codon and complete loss of CD33 expression: another key variant with potential impact on response to CD33-directed agents. Leuk Lymphoma. 2019 Feb 5:1-4.PubMed PMID: 30721105.
38. Bargal, S, Roya R, Crews K, Wu H, Cao X, Rubnitz R, Ribeiro R, Downing J, POunds S, **Lamba JK.** Genome-wide association analysis identifies SNPs predictive of *in vitro* leukemic cell sensitivity to cytarabine in pediatric AML. Oncotarget 2018;9(79):34859-34875
39. Elsayed A, Cao X, Crews KR, Gandhi V, Plunkett W, Rubnitz JE, Ribeiro R, Pounds S and **Lamba JK**. Comprehensive Ara-C SNP score (ACSS) predicts leukemic cell intracellular ara-CTP levels in pediatric AML patients. Pharmacogenomics, 2018 Sep 1; 19914)1101-1110 PMID: 30088438
40. Gbadamosi M, Meshinchi S and **Lamba JK**. Gemtuzumab Ozogamicin for treatment of newly diagnosed CD33 positive acute myelioid leukemia. Future Oncology. 2018 Jul24; PMID 30339981.
41. **Lamba JK**, Cao X, Raimondi SC, Rafiee R, Downing JR, Lei S, Gruber T, Ribeiro RC, Rubnitz JE and Pounds S. Integrated epigenetic and genetic analysis identifies markers of prognostic significance in pediatric acute myeloid leukemia. Oncotarget 2018, 9:26711-26723.

42. Stockard B, Garrett T, Guingab-Cagmat J, Meshinchi S, **Lamba J**. Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia. Sci Rep. 2018 Apr 3;8(1):5534. doi: 10.1038/s41598-018-23863-9. PubMed PMID: 29615816; PubMed Central PMCID: PMC5882915
43. **Lamba JK**, Voigt AP, Chauhan L, Shin M, Aplenc R, Eidenschink Brodersen L, Gamis AS, Meshinchi S, Loken MR. CD33 splicing SNP regulates expression levels of CD33 in normal regenerating monocytes in AML patients. Leuk Lymphoma. 2018 Jan 10:1-4. doi: 10.1080/10428194.2017.1421756. PubMed PMID: 29320902.
44. **Lamba JK, Chauhan L, Shin M, Loken M, Pollard J, Wang Y-C, Ries R, Aplenc R, Hirsch B, Raimondi R, Walter R, Bernstein ID, Gamis AS, Alonzo TA and Meshinchi S. CD33 Splicing polymorphism determines gemtuzumab ozogamicin response in de novo AML: report from randomized phase III Children's Oncology Group Trial AAML0531. Journal of Clinical**

Oncology 2017.PMID: 2864474.
45. Drusbosky L, Medina C, Martuscello R, Hawkins KE, Chang M, **Lamba JK**, Vali S,Kumar A, Singh NK, Abbasi T, Sekeres MA, Mallo M, Sole F, Bejar R, Cogle CR. Computational drug treatment simulations on projections of dysregulated protein networks derived from the myelodysplastic mutanome match clinical response in patients. Leuk Res. 2017 Jan;52:1-7. PMID: 27855285
46. Cao X, Crews KR, Downing J, **Lamba J** and Pounds SB. CC-PROMISE effectively integrates two forms of molecular data with multiple biologically related endpoints. BMC Bioinformatics. 2016, 17; (Suppl 13); 382. PMID 27766934.
47. Laszlo GS, Harrington KH, Gudgeon CJ, Beddoe ME, Fitzgibbon MP, Ries RE, **Lamba JK**, McIntosh MW, Meshinchi S, Walter RB. Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia. Oncotarget. 2016. PMID: 27248327.
48. Bhise NS, Chauhan L, Shin M, Cao X, Pounds S, Lamba V and **Lamba J**. MicroRNA-mRNA pairs associated with outcome in AML: from invitro cell based studies to AML patients. Frontiers in 2016;6:324.PMID: 26858643
49. Fridley BL, Ghosh TM, Wang A, Raghavan R, Dai J, Goode EL **Lamba JK**. Genome-wide study of response to platinum, taxane and combination therapy in ovarian cancer: In vitro phenotypes, inherited variation and disease recurrence. Frontiers in Genetics 2016; 227;37 PMID: 27047539;PMCID: PMC4801852
50. Ghodke-Puranik Y, Puranik AS, Shintre P, Joshi K, Patwardhan B, **Lamba J**,Niewold TB, Chopra A. Folate metabolic pathway single nucleotide polymorphisms: a predictive pharmacogenetic marker of methotrexate response in Indian (Asian) patients with rheumatoid arthritis. Pharmacogenomics. 2015;16(18):2019-34. PMID: 26616421
51. Chauhan L, Jenkins GD, Bhise N, Feldberg T, Mitra-Gosh T, Fridley BL, **Lamba JK** Genome-wide association analysis identified splicing single nucleotide polymorphism in CFLAR predictive of triptolide chemo-sensitivity. BMC Genomics.2015, 30; 16; 483. PMID: 26121980; PMCID: PMC: 4485866
52. **Lamba JK**, Pounds S, Cao X, Crews KR, Cogle CR, Bhise N, Raimondi SC, Downing JR, Baker SD, Ribeiro RC, Rubnitz JE. Clinical significance of In vivo Cytarabine Induced Gene Expression Signature in AML. Leuk Lymphoma. 2015 Sep 14:1-31. PMID: 26366682.
53. **Lamba JK**, Fridley BL, Ghosh TM, Yu Q, Mehta G, Gupta P. Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer. Pharmacogenomics. 2014;15(12):1565-74. PMID: 25340731.
54. Bachanova V, Shanley R, Malik F, Chauhan L, Lamba V, Weisdorf DJ, Burns LJ, **Lamba JK**. Cytochrome P450 2B6*5 Increases Relapse after Cyclophosphamide-Containing Conditioning and Autologous Transplantation for Lymphoma. Biol Blood Marrow Transplant. 2015 May;21(5):944-8. PMID: 25677220.
55. Alvarellos ML, **Lamba J**, Sangkuhl K, Thorn CF, Wang L, Klein DJ, Altman RB, Klein TE. PharmGKB summary: gemcitabine pathway. Pharmacogenet Genomics. 2014 Nov;24(11):564-74 PMID: 25162786; PMCID: PMC4189987.
56. Burke MJ, **Lamba JK**, Pounds S, Cao X, Ghodke-Puranik Y, Lindgren BR, Weigel BJ, Verneris MR, Miller JS. A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2014 Sep;89(9):889-95. PMID: 24891274; PMCID: PMC4134715.
57. Lamba V, Ghodke-Puranik Y, Guan W, **Lamba JK**. Identification of suitable reference genes for hepatic microRNA quantitation. BMC Res Notes. 2014 Mar 7;7:129. PMID: 24606728; PMCID: PMC3995942.
58. Khatri A, Williams BW, Fisher J, Brundage RC, Gurvich VJ, Lis LG, Skubitz KM, Dudek AZ, Greeno EW, Kratzke RA, **Lamba JK**, Kirstein MN. SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours. Br J Cancer. 2014 Jan 21;110(2):304-12. PMID: 24300978; PMCID: PMC3899768.
59. Cao X, Mitra AK, Pounds S, Crews KR, Gandhi V, Plunkett W, Dolan ME, Hartford C, Raimondi S,

Campana D, Downing J, Rubnitz JE, Ribeiro RC, **Lamba JK**. RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients. Pharmacogenomics. 2013 Sep;14(12):1449-66. PMID: 24024897; PMCID: PMC3860742.

60. Gamazon ER, **Lamba JK**, Pounds S, Stark AL, Wheeler HE, Cao X, Im HK, Mitra AK, Rubnitz JE, Ribeiro RC, Raimondi S, Campana D, Crews KR, Wong SS, Welsh M, Hulur I, Gorsic L, Hartford CM, Zhang W, Cox NJ, Dolan ME. Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients. Blood. 2013 May 23;121(21):4366-76. PMID: 23538338; PMCID: PMC3663430.
61. Ghodke-Puranik Y, Thorn CF, **Lamba JK**, Leeder JS, Song W, Birnbaum AK, Altman RB, Klein TE. Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2013 Apr;23(4):236-41PMID: 23407051;PMCID: PMC3696515.
62. Mortland L, Alonzo TA, Walter RB, Gerbing RB, Mitra AK, Pollard JA, Loken MR, Hirsch B, Raimondi S, Franklin J, Pounds S, Cao X, Rubnitz JE, Ribeiro RC, Gamis A, Meshinchi S, **Lamba JK**. Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy. Clin Cancer Res. 2013 Mar 15;19(6):1620-7. PMID: 23444229; PMCID: PMC3602123.

NOTE: This article was highlighted on several news media and websites

63. Puranik YG, Birnbaum AK, Marino SE, Ahmed G, Cloyd JC, Remmel RP, Leppik IE, **Lamba JK**. Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics. 2013 Jan;14(1):35-45. PMID: 23252947; PMCID: PMC3570048.
64. Ghodke Y, Anderson PL, Sangkuhl K, **Lamba J**, Altman RB, Klein TE. PharmGKB summary: zidovudine pathway. Pharmacogenet Genomics. 2012 Dec;22(12):891-4. PMID: 22960662; PMCID:PMC3696524.
65. Pakhomov S, McInnes BT, **Lamba J**, Liu Y, Melton GB, Ghodke Y, Bhise N, Lamba V, Birnbaum AK. Using PharmGKB to train text mining approaches for identifying potential gene targets for pharmacogenomic studies. J Biomed Inform. 2012 Oct;45(5):862-9. PMID:22564551; PMCID: PMC3438361.
66. Moen M, **Lamba J**. Assessment of healthcare students' views on pharmacogenomics at the University of Minnesota. Pharmacogenomics. 2012 Oct;13(13):1537-45. PMID: 23057552; PMCID: PMC3562085.
67. Thirumaran RK, **Lamba JK**, Kim RB, Urquhart BL, Gregor JC, Chande N, Fan Y, Qi A, Cheng C, Thummel KE, Hall SD, Schuetz EG. Intestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation. Biochem Pharmacol. 2012 Jul 1;84(1):104-12. PMID: 22484315; PMCID: PMC3774043.
68. **Lamba J**, Hebert JM, Schuetz EG, Klein TE, Altman RB. PharmGKB summary: very important pharmacogene information for CYP3A5. Pharmacogenet Genomics. 2012Jul;22(7):555-8. PMID: 22407409; PMCID: PMC3738061.
69. Mitra AK, Kirstein MN, Khatri A, Skubitz KM, Dudek AZ, Greeno EW, Kratzke RA,**Lamba JK**. Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors. Pharmacogenomics. 2012 Jul;13(9):1009-21. PMID: 22838949.
70. Jensen K, Johnson LA, Jacobson PA, Kachler S, Kirstein MN, **Lamba J**, Klotz KN. Cytotoxic purine nucleoside analogues bind to A1, A2A, and A3 adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol. 2012 May;385(5):519-25. PMID: 22249336, PMCID: PMC3831620.
71. Kohli M, Riska SM, Mahoney DW, Chai HS, Hillman DW, Rider DN, Costello BA,Qin R, **Lamba J**, Sahasrabudhe DM, Cerhan JR. Germline predictors of androgen deprivation therapy response in advanced prostate cancer. Mayo Clin Proc. 2012 Mar;87(3):240-6. PMID: 22386179; PMCID: PMC3538410.
72. Brown KC, Hosseinipour MC, Hoskins JM, Thirumaran RK, Tien HC, Weigel R, Tauzie J, Shumba

l, **Lamba JK,** Schuetz EG, McLeod HL, Kashuba AD, Corbett AH. Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians. Pharmacogenomics. 2012 Jan;13(1):113-21PMID: 22111602; PMCID: PMC3292264.

73. **Lamba JK**. Pharmacogenomics of cytarabine in childhood leukemia. Pharmacogenomics. 2011 Dec;12(12):1629-32. PMID: 22118048.
74. Mitra AK, Crews KR, Pounds S, Cao X, Feldberg T, Ghodke Y, Gandhi V, Plunkett W, Dolan ME, Hartford C, Raimondi S, Campana D, Downing J, Rubnitz JE, Ribeiro RC, **Lamba JK**. Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia. J Pharmacol Exp Ther. 2011 Oct;339(1):9-23.PMID: 21712425; PMCID: PMC3186292.
75. Mitra AK, Crews K, Pounds S, Cao X, Downing JR, Raimondi S, Campana D, Ribeiro RC, Rubnitz JE, **Lamba JK**. Impact of genetic variation in FKBP5 on clinical response in pediatric acute myeloid leukemia patients: a pilot study. Leukemia. 2011 Aug;25(8):1354-6. PMID: 21483441; PMCID: PMC3238383.
76. Mitra R, Guo Z, Milani M, Mesaros C, Rodriguez M, Nguyen J, Luo X, Clarke D**, Lamba J**, Schuetz E, Donner DB, Puli N, Falck JR, Capdevila J, Gupta K, Blair IA, Potter DA. CYP3A4 mediates growth of estrogen receptor-positive breast cancer cells in part by inducing nuclear translocation of phospho-Stat3 through biosynthesis of (±)-14,15-epoxyeicosatrienoic acid (EET). J Biol Chem. 2011 May 20;286(20):17543-59. PMID:21402692; PMCID: PMC3093829.
77. Wilke RA, Xu H, Denny JC, Roden DM, Krauss RM, McCarty CA, Davis RL, Skaar T, **Lamba J**, Savova G. The emerging role of electronic medical records in pharmacogenomics. Clin Pharmacol Ther. 2011 Mar;89(3):379-86. PMID: 21248726;PMCID: PMC3204342.
78. **Lamba JK**, Crews KR, Pounds SB, Cao X, Gandhi V, Plunkett W, Razzouk BI, Lamba V, Baker SD, Raimondi SC, Campana D, Pui CH, Downing JR, Rubnitz JE, Ribeiro RC. Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes. Pharmacogenomics. 2011 Mar;12(3):327-39. PMID: 21449673; PMCID: PMC3139433.
79. Thorn CF, **Lamba JK**, Lamba V, Klein TE, Altman RB. PharmGKB summary: very important pharmacogene information for CYP2B6. Pharmacogenet Genomics. 2010 Aug;20(8):520-3. PubMed PMID: 20648701; PubMed Central PMCID: PMC3086041.
80. Chaudhry AS, Urban TJ, **Lamba JK**, Birnbaum AK, Remmel RP, Subramanian M, Strom S, You JH, Kasperaviciute D, Catarino CB, Radtke RA, Sisodiya SM, Goldstein DB, Schuetz EG. CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose. J Pharmacol Exp Ther. 2010 Feb;332(2):599-611. PMID: 19855097; PMCID: PMC2812115.
81. **Lamba JK**. Genetic factors influencing cytarabine therapy. Pharmacogenomics. 2009 Oct;10(10):1657-74. PMID: 19842938; PMCID: PMC2828057.
82. Pounds S, Cheng C, Cao X, Crews KR, Plunkett W, Gandhi V, Rubnitz J, Ribeiro RC, Downing JR, **Lamba J**. PROMISE: a tool to identify genomic features with a specific biologically interesting pattern of associations with multiple endpoint variables. Bioinformatics. 2009 Aug 15;25(16):2013-9. PMID: 19528086; PMCID: PMC2723006.
83. Hartford CM, Duan S, Delaney SM, Mi S, Kistner EO, **Lamba JK**, Huang RS, Dolan ME. Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood. 2009 Mar 5;113(10):2145-53. PMID: 19109566; PMCID: PMC2652364.
84. **Lamba JK**, Pounds S, Cao X, Downing JR, Campana D, Ribeiro RC, Pui CH, RubnitzJE. Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot study. Leukemia. 2009 Feb;23(2):402-4. PMID: 18615103; PMCID: PMC2659556.
85. Roberts PJ, Rollins KD, Kashuba AD, Paine MF, Nelsen AC, Williams EE, Moran C, **Lamba JK**, Schuetz EG, Hawke RL. The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans. Drug Metab Dispos. 2008 Aug;36(8):1465-9. PMID: 18490434; PMCID: PMC2770345.

86. Poonkuzhali B, **Lamba J**, Strom S, Sparreboom A, Thummel K, Watkins P, Schuetz E. Association of breast cancer resistance protein/ABCG2 phenotypes and novel promoter and intron 1 single nucleotide polymorphisms. Drug Metab Dispos. 2008 Apr;36(4):780-95. PMID: 18180275.
87. Isoherranen N, Ludington SR, Givens RC, **Lamba JK**, Pusek SN, Dees EC, Blough DK, Iwanaga K, Hawke RL, Schuetz EG, Watkins PB, Thummel KE, Paine MF. The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation. Drug Metab Dispos. 2008 Jan;36(1):146-54. PMID: 17954524.
88. **Lamba J,** Lamba V, Strom S, Venkataramanan R, Schuetz E. Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab Dispos.2008 Jan;36(1):169-81. Epub 2007 Oct 9. PMID: 17925385.
89. **Lamba JK**. Pharmacogenetics of the constitutive androstane receptor. Pharmacogenomics. 2008 Jan;9(1):71-83. Review. PMID: 18154449.
90. **Lamba JK**, Crews K, Pounds S, Schuetz EG, Gresham J, Gandhi V, Plunkett W, Rubnitz J, Ribeiro R. Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J Pharmacol Exp Ther. 2007 Dec;323(3):935-45. PMID: 17855478.
91. Altman RB, Benowitz N, Gurwitz D, Lunshof J, Relling M, **Lamba J**, Wieben E, Mooney S, Giacomini K, Weiss S, Johnson JA, McLeod H, Flockhart D, Weinshilboum R, Shuldiner AR, Roden D, Krauss RM, Ratain M. Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing. Pharmacogenomics. 2007 May;8(5):519. PubMed PMID: 17465717.
92. Vyas PM, Roychowdhury S, Khan FD, Prisinzano TE, **Lamba J**, Schuetz EG, Blaisdell J, Goldstein JA, Munson KL, Hines RN, Svensson CK. Enzyme-mediated protein haptenation of dapsone and sulfamethoxazole in human keratinocytes: I. Expression and role of cytochromes P450. J Pharmacol Exp Ther. 2006 Oct;319(1):488-96 PMID: 16857728.
93. Anderson PL, **Lamba J**, Aquilante CL, Schuetz E, Fletcher CV. Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J Acquir Immune Defic Syndr. 2006 Aug 1;42(4):441-9. PMID: 16791115.
94. **Lamba JK**, Chen X, Lan LB, Kim JW, Wei Wang X, Relling MV, Kazuto Y, Watkins PB, Strom S, Sun D, Schuetz JD, Schuetz EG. Increased CYP3A4 copy number in TONG/HCC cells but not in DNA from other humans. Pharmacogenet Genomics. 2006 Jun;16(6):415-27. PMID: 16708050.
95. **Lamba J**, Strom S, Venkataramanan R, Thummel KE, Lin YS, Liu W, Cheng C, Lamba V, Watkins PB, Schuetz E. MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin Pharmacol Ther. 2006 Apr;79(4):325-38. Epub 2006 Feb 20. PubMed PMID: 16580901.
96. Song P, **Lamba JK**, Zhang L, Schuetz E, Shukla N, Meibohm B, Yates CR. G2677T and C3435T genotype and haplotype are associated with hepatic ABCB1 (MDR1) expression. J Clin Pharmacol. 2006 Mar;46(3):373-9. PMID: 16490813.
97. Mouly SJ, Matheny C, Paine MF, Smith G, **Lamba J,** Lamba V, Pusek SN, Schuetz EG, Stewart PW, Watkins PB. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P4503A5. Clin Pharmacol Ther. 2005 Dec;78(6):605-18. PMID: 16338276.
98. **Lamba J**, Lamba V, Schuetz E. Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. Curr Drug Metab. 2005 Aug;6(4):369-83. Review. PMID: 16101575.
99. Zheng H, Schuetz E, Zeevi A, Zhang J, McCurry K, Webber S, Iacono A, **Lamba J**, Burckart GJ. Sequential analysis of tacrolimus dosing in adult lung transplant patients with ABCB1 haplotypes. J Clin Pharmacol. 2005 Apr;45(4):404-10.PMID: 15778421.
100. Zheng HX, Zeevi A, McCurry K, Schuetz E, Webber S, Ristich J, Zhang J, Iacono A, Dauber J, McDade K, Zaldonis D, **Lamba J**, Burckart GJ. The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients. Transpl Immunol. 2005 Mar;14(1):37-42.

PMID:15814280.
101. Zheng HX, Webber SA, Zeevi A, Schuetz E, Zhang J, **Lamba J,** Boyle GJ, Wilson JW, Burckart GJ. The impact of pharmacogenomic factors on steroid dependency in pediatric heart transplant patients using logistic regression analysis. Pediatr Transplant. 2004 Dec;8(6):551-7. PMID: 15598322.
102. **Lamba JK**, Lamba V, Yasuda K, Lin YS, Assem M, Thompson E, Strom S, Schuetz E. Expression of constitutive androstane receptor splice variants in human tissues and their functional consequences. J Pharmacol Exp Ther. 2004 Nov;311(2):811-21. Epub 2004 Jun 11. PMID: 15194709.
103. Lamba V, Yasuda K, **Lamba JK**, Assem M, Davila J, Strom S, Schuetz EG. PXR (NR1I2): splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators. Toxicol Appl Pharmacol. 2004 Sep 15;199(3):251-65. PubMed PMID: 15364541.
104. Schuetz EG, Relling MV, Kishi S, Yang W, Das S, Chen P, Cook EH, Rosner GL, Pui CH, Blanco JG, Edick MJ, Hancock ML, Winick NJ, Dervieux T, Amylon MD, Bash RO, Behm FG, Camitta BM, Raimondi SC, Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, **Lamba J**, Lim R, Lim HL, Ong AB, Lee HS, Kuehl P, Zhang J, Lin Y, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS. PharmGKB update: II. CYP3A5, cytochrome P450, family 3, subfamily A, polypeptide 5. Pharmacol Rev. 2004 Jun;56(2):159. PMID: 15169924.
105. Zheng H, Zeevi A, Schuetz E, **Lamba J**, McCurry K, Griffith BP, Webber S, Ristich J, Dauber J, Iacono A, Grgurich W, Zaldonis D, McDade K, Zhang J, Burckart GJ. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J Clin Pharmacol. 2004 Feb;44(2):135-40. PMID: 14747421.
106. Lamba V, **Lamba J,** Yasuda K, Strom S, Davila J, Hancock ML, Fackenthal JD, Rogan PK, Ring B, Wrighton SA, Schuetz EG. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther. 2003 Dec;307(3):90 22. PMID: 14551287.
107. Givens RC, Lin YS, Dowling AL, Thummel KE, **Lamba JK**, Schuetz EG, Stewart PW, Watkins PB. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol (1985). 2003 Sep;95(3):1297-300. Epub 2003 May16. PMID: 12754175.
108. Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Bowman P, Boyle G, Law Y, Miller S, **Lamba J**, Burckart GJ. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 2003 Apr;3(4):477-83. PubMed PMID: 12694072.
109. Kadlubar FF, Berkowitz GS, Delongchamp RR, Wang C, Green BL, Tang G, **Lamba J**, Schuetz E, Wolff MS. The CYP3A4*1B variant is related to the onset of puberty a known risk factor for the development of breast cancer. Cancer Epidemiol Biomarkers Prev. 2003 Apr;12(4):327-31. PubMed PMID: 12692107.
110. **Lamba JK**, Adachi M, Sun D, Tammur J, Schuetz EG, Allikmets R, Schuetz JD. Nonsense mediated decay downregulates conserved alternatively spliced ABCC4 transcripts bearing nonsense codons. Hum Mol Genet. 2003 Jan 15;12(2):99 -109. PMID: 12499391.
111. Zamber CP, **Lamba JK**, Yasuda K, Farnum J, Thummel K, Schuetz JD, Schuetz EG. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics. 2003 Jan;13(1):19-28. PubMed PMID: 12544509.
112. **Lamba JK**, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002 Nov 18;54(10):1271-94. Review. PMID: 12406645.
113. Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, **Lamba J**, Bowman P, Burckart GJ. The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. Hum Immunol. 2002 Sep;63(9):765-70. PMID: 12175731.
114. Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, **Lamba J**, Schuetz E, Lim R, Lim HL, Ong AB, Lee

HS. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol. 2002 Sep 1;20(17):3683-90. PMID: 12202670.
115. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, **Lamba J**, Schuetz EG, Thummel KE. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol. 2002 Jul;62(1):162-72. PMID: 12065767.
116. **Lamba JK**, Lin YS, Thummel K, Daly A, Watkins PB, Strom S, Zhang J, Schuetz EG. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics. 2002 Mar;12(2):121-32. PMID: 11875366.
117. **Lamba JK**, Dhiman RK, Singh R, Kohli KK. Correlation between omeprazole hydroxylase and CYP2C19 genotype in North Indians. Eur J Clin Pharmacol. 2001 Nov;57(9):649-52. PMID: 11791894
118. Schuetz EG, Strom S, Yasuda K, Lecureur V, Assem M, Brimer C, **Lamba J**, Kim RB, Ramachandran V, Komoroski BJ, Venkataramanan R, Cai H, Sinal CJ, Gonzalez FJ, Schuetz JD. Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J Biol Chem. 2001 Oct 19;276(42):39411-8. PMID: 11509573.
119. Kuehl P, Zhang J, Lin Y, **Lamba J**, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001 Apr;27(4):383-91. PMID: 11279519.
120. **Lamba JK**, Dhiman RK, Kohli KK. CYP2C19 genetic mutations in North Indians. Clin Pharmacol Ther. 2000 Sep;68(3):328-35. PubMed PMID: 11014415.
121. Lamba V, **Lamba JK**, Dilawari JB, Kohli KK. Genetic polymorphism of CYP2D6 in North Indian subjects. Eur J Clin Pharmacol. 1998 Nov-Dec;54(9-10):787-91. PMID: 9923585.
122. **Lamba JK**, Dhiman RK, Kohli KK. Genetic polymorphism of the hepatic cytochrome P450 2C19 in north Indian subjects. Clin Pharmacol Ther. 1998 Apr;63(4):422-7. PubMed PMID: 9585796.

Book Chapters

1 **Lamba JK** and Schuetz E. Chapter 9. Genetic variants of xenobiotic Receptors and their implications in drug metabolism and pharmacogenetics. Book Title: Nuclear receptors in Drug Metabolism. 2009 John Wiley & Sons

2. Bhise N, Chauhan L and **Lamba JK.** Chapter 19. Pharmacogenetic studies in pediatric acute myeloid leukemia. Book Title: Genome-Wide Association Studies- From polymorphisms to Personalized Medicine. 2016 Cambridge University Press

3. Ghodke-Puranik YA and **Lamba JK**. Chapter 7: Pharmacogenomics. Book Title: Innovative Approaches in Drug Discovery: Ethnopharmacology, Systems Biology and Holistic Targeting 2016, Elsvier Inc.

4. Lamba JK **Chapter 193:** Pharmacogenomics in Hematological Malignancies, 2023, to be released September 2023

INVITED SEMINARS

1. Lighting up naked DNA: A real time in vivo transcription assay and other applications of hydrodynamic infusion and whole body imaging. 4thAnnual Tennessee Mouse Genome Consortium (TMGC) retreat, Nashville, Tennessee, USA, 2003.
2. Imaging-Based In Vivo Transcription Studies in Mice. 2005 Annual AAPS Meeting (American Association of Pharmaceutical Scientists) Nashville; November 2005.
3. Pharmacogenomics of Ara-C metabolic Pathway. Clinical Pharmacology and Pharmacogenomics weekly Conference. University of Chicago, Chicago, March 29th 2007.
4. 2007 ASPET Meeting, Washington DC; April-May 2007.

5. Pharmacogenomics of anticancer nucleoside analogs, FDA, Baltimore (June, 2010)
6. Pharmacogenomics of ara-C in AML, PGIMER, India (March 2010)
7. Plenary session 3 Speaker at ISSX meeting, Dallas TX, Oct 2012: 'Regulatory polymorphisms and their impact on inter-individual differences in drug disposition and response.
8. Clinical impact of CD33 SNPs in treatment outcome to GO in AML patients: COG annual Meeting, Atlanta, Oct 2012
9. International Conference on Functional and Comparative Genomics & Pharmacogenomics; Pharmacogenomics in AML-A road towards personalized Medicine November 2013, Chicago
10. Invited Speaker University of Illinois Chicago: Pharmacogenomics in AML- A road towards personalized Medicine. Jan 2014
11. Pharmacogenomics of Ara-C metabolic Pathway Phar 8100: University of Minnesota, Experimental and Clinical Pharmacology, 2008
12. Pharmacogenomics of cytarabine in Acute Myeloid Leukemia, Masonic Cancer Center Seminar Series, University of Minnesota. Dec, 2009
13. Pharmacogenomics of cytarabine: a road towards personalized medicine in Acute Myeloid Leukemia. Garibaldi Conferences, University of Minnesota. Jan, 2010
14. Pharmacogenomics of cytarabine in Acute Myeloid Leukemia, Leukemia Research Seminar Series, University of Minnesota. Nov 2009.
15. Pharmacogenomics of cytarabine: a road towards personalized medicine in Acute Myeloid Leukemia. Lab Medicine and Pathology Grand Rounds, University of Minnesota. April 2011,
16. 'Pharmacogenomics in Acute Myeloid Leukemia', Masonic Cancer center Research Symposium May 30, 2012
17. 'Pharmacogenomics in AML-a road towards personalized Medicine'. Experimental and Clinical Pharmacology Departmental Seminar Series, 2013
18. 'Genetic Variation as determinants of outcome in Acute Myeloid Leukemia'. UF Hematological Malignancies and Bone Marrow Transplant Retreat. University of Florida, Nov 2015
19. 'Integrated Genomics/Epigenomics approaches to advance precision medicine in acute Myeloid Leukemia', UC Davies Comprehensive Cancer Center- Cancer Biology Research Seminar Series, Sacramento. April 28, 2016
20. 'Integrated Genomics and Epigenomics approaches to advance therapy for pediatric AML.' Children's Mercy Hospital, Kansas MO, Nov 10-11, 2016
21. 'Integrated Genomics and Epigenomics approaches to advance precision medicine in acute Myeloid Leukemia', St Jude Grand Rounds. St. Jude Children's Research Hospital, Memphis TN, Jan 25-26, 2016.
22. 'Integrated genetic and epigenetic analysis identifies biomarkers of prognostic significance in pediatric acute myeloid leukemia'. 9th International Conference on Genomics and Pharmacogenomics June 15-16, 2017 London, UK
23. 'Multi-omics approaches to advance treatment strategies in pediatric AML'. Invited Seminar, University of Buffalo, School of Pharmacy, Buffalo New York, Oct-18, 2018.
24. 'Multi-Omics approaches to advance personalized therapy in AML'. University of Florida Grand Rounds, Jan 2019, Gainesville FL
25. 'Genomic Approaches to Identify Markers Predictive of Response and Novel Targets in AML' 3rd University of Florida Drug discovery symposium, April 25th, 2019, Hotel Infosys, Gainesville Florida
26. 'Pharmacogenomics in pediatric AML', 12th Global Gators symposium, Reims, France, June 29th 2019
27. "Path to precision medicine in Acute myeloid Leukemia'. Grand Rounds, Hematology/ Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India, January 7th 2020
28. "Pharmacogenomics for potential personalization of AML treatment". Hem Malignancies Program, St Jude Children's Research Hospital, Memphis TN, (Virtual presentation) September 2020

29. "Genomics Guided Precision Medicine in Pediatric AML" UFHCC, Topics in Cancer, (Virtual Presentation) November, 2020.
30. "Genomics Guided Precision Medicine in Pediatric AML" Pediatric Malignancies Program Retreat, University of California San Francisco (UCSF), (Virtual Presentation) Dec 2nd, 2020.
31. European Society of Human Genetics Annual meeting "Current and Future Prospects of the Pharmacogenomics of CD33-Targeted Immunotherapy in Leukemia " (Virtual), Aug 28-31 2021
32. Genomics Guided Precision Medicine In Pediatric Acute Myeloid Leukemia" Children's Oncology Group meeting. Aug16th, 2021
33. ECOG- Leukemia meeting "Polygenic risk scores to personalize AML treatment." Oct 6th 2021
34. Seminar speaker University of Alabama Auburn-" Pharmacogenomics in AML" October 12, 2021
35. Presentation at St Jude Heme-Maligancies Program "Leukemic stemness based-Transcriptomic and Ara-C and Gemtuzumab based-PGx score to personalize AML treatment "March 23rd, 2022.
36. Presentation at Children's Oncology Group monthly meeting "Pharmacogenomics to personalize AML treatment" April 7th 2022
37. Presentation at the UFHCC Pediatric Immunotherapy Initiative group meeting.
38. 'Paths to precision medicine in acute myeloid leukemia' Pharm Talks, University of Florida, College of Pharmacy, May 16th, 2022.
39. 'Pharmacogenomics to personalize acute myeloid treatment', 13th Global Gators symposium, Basel, Switzerland June 3-4th 2022
40. 'Transcriptomic and genomic scores to personalize Acute Myeloid Leukemia treatment. Christian Medical College, Vellore, India, Jun 17th 2022
41. 'Pharmacogenomics in Clinical Medicine' Postgraduate Institute of Medical Education and Research, Chandigarh, India, Jun 21, 2022.
42. 'Genomic scores to personalize AML treatment' Postgraduate Institute of Medical Education and Research, Chandigarh India, Jun 20th, 2022.
43. "Time to reconsider CD33 single nucleotide polymorphism for CD targeted treatment response" Invited Speaker City of Home Oakland TMI monthly meeting – Aug 5, 2022
44. "AML treatment personalization using transcriptomics and pharmacogenomics based scores" PGRN Monthly Research in seminar, December 9, 2023
45. "Integrated Systems Biology of AML" UFHCC-UF Scripps Retreat Speaker, February 16, 2023
46. Presenter, Women's History celebration month, College of Pharmacy, University of Florida, March 7, 2023
47. Invited speaker: "Polygenic Ara-C SNP Score groups to match most effective remission induction regimen in pediatric AML" Purine Pyrimidine Society Symposium, Los Angeles, Jun 26-29, 2023
48. Invited speaker, HEMATOCON meeting, Nov 2-5, 2023 Bhuvneshwar India.

TEACHING AND INSTRUCTION

University of Florida:

- PHA5933: Clinical Applications of Pharmacogenomics (Fall 2014, Fall 2015)
- PHA5113: Personalized Medicine (Fall 2014, Fall 2015, Fall 2016)
- PHA5728: Patient Care 2 (Fall 2016- present): Topic -Precision Medicine in Oncology
- PHA5785:Patient Care 5 (Spring 2017-2021): Precision Medicine in Breast Cancer
- Intro to Graduate skills (Spring 2017-present)
- Life cycle of a drug (Summer 2017-present)
- PH6427: Pharmacogenetics of Drug metabolism and Transport (Fall, 2018, 2019, 2021, 2023).
- GMS: Precision Medicine in Oncology (Fall 2019)

University of Minnesota:

- PHAR6726: Principles of Pharmacology (2.3 credits) (Spring 2014): Teaching 6 lectures on pharmacogenomics in this required course for first year PharmD students (n=169).
- PHAR6224: Pharmacogenomics Genetic Basis for Variability in Drug Response (2 credits-in class) (Spring 2010, 2011, 2012): Elective course offered to 2nd and 3rd yr PharmD and graduate students.
- PHAR6224: Pharmacogenomics: Genetic Basis for Variability in Drug Response (2 credits-online) (Spring 2012, 2013, 2014): interactive online elective course offered to 2nd and 3rd yr PharmD and external students.

As a course director for both online and face to face versions of PHAR6224, I was involved in all aspects ranging from syllabus preparation, preparing exams and quizzes, lecture assignments and assessment surveys at multiple time points during the course. In class time (30 contact hrs); outside class time (~30 contact hrs).

- MICB4994 001 Directed Research: Undergraduate students in College of Biosciences. (10 contact hrs/semester)
- ECP 8100 /PHAR6160H: ECP graduate student Seminars (1 credit): Course director and faculty facilitator for 2011 Fall semester and 2012 and 2013 Fall and Spring semesters.
- PUBH 6160: Metabolomics course (3 credits) (Spring 2011 and 2013): As a Lecturer covered topics on genomics and pharmacogenomics.
- ECP 5620 - Drug Metabolism and Disposition (2 credits) (Spring 2011 and 2013) as a Lecturer covered topics on Pharmacogenomics of Phase I drug metabolizing enzymes
- Garibaldi Seminar series for Hematology-oncology fellows 2010 (4 contact hrs)

University of Tennessee Health Sciences Center

- Drug Metabolism course for graduate students at University of Tennessee Health Sciences Center, Memphis TN. 2008: 4 contact hrs.

STUDENTS MENTORED

Pediatric Oncology Education (POE) Program St. Jude Children's Research Hospital

- Alexis Stephens, Texas Southern University, 2004 (currently in medical school)
- Jessica Gresham, Auburn University, Auburn, AL 2005, 2006 (currently in Pharmacy school)
- Vanessa Maneses, University of Illinois Urbana-Champaign, 2006, Vanessa received 3rd prize for best POE basic science paper
- Brittney Green, 2007
- Jeremy Hunt, 2007

Undergrad students, University of Minnesota

- Michael Hart UROP, 2009, UROP 2010, Directed research, CBS, University of Minnesota
- Gautham Kartha UROP 2009, CBS, University of Minnesota
- Kaylee Myhre 2009 Summer scholar Veterinary Medicine school, University of Minnesota
- Thomas Matthew Gentle III from Anoka Ramsey Community College (Summer scholar sponsored by ISRP-Independent Research Summer program), summer, 2010
- Lauren Wigen, Summer 2010

Undergrad students, University of Florida

- Katherine Rajschmir (2017-2018)
- Jasmin Yu (2018)
- Kahai Nguyen (2018)
- Fernando Sckaff (2022-2023)

Hematology-Oncology Clinical Fellows, University of Minnesota

- Dr. Leslie Smith Mortland(2009-2011) funded through Children's Cancer Research Fund (CCRF)
- Dr. Jenny McCormick (2009-2011) funded through Children's Cancer Research Fund (CCRF)
- Dr. Maggie Skrypek (2012-2014) funded through Children's Cancer Research Fund (CCRF)

Pharm D students
University of Minnesota

- Jennifer Wilson (2009-2010, Administrative advisor- University of Minnesota)
- Akil Hamed (2010-2011, Administrative advisor and content advisor- University of Minnesota)
- Wen Song (2011-2012, Content advisor- University of Minnesota)
- Megan Moen (2011-2012, Content advisor- University of Minnesota)
- Joshua Tempesta (2011-2012, Administrative advisor and content advisor- University of Minnesota)
- Alicia Gunterus (2012 summer Melendy Scholar- University of Minnesota)
- Tiffany Chan 2013-2014, Content advisor- University of Minnesota)
- Pedro Warff (2013-2014, Administrative advisor- University of Minnesota)

University of Florida

- Sally Kassem (UF PharmD 2015-2015, Summer Research Mentor- University of Florida and Directed Research Fall 2015)
  Recipient of Best Poster Award- Pharm D category, UF, CoP Research day 2016)
- Emile Bergsma (UF PharmD 2015, Summer Research mentor and Directed Research- Fall 2015)
- Charles Davis- FAMU (2016 –Summer Research mentor)
- Andrew Asante (ISRP: Summer 2018)
- Elham – Visiting scientist from Egypt (2016)
- Natasha Smith (UF PharmD 2019-2021)
- Angelica de Jesus Sosa (UF PharmD 2019-2021)
- Alessandra Diioia (UF PharmD 2019- 2020)
- Akhila Dadwai (2019-2020) International Pharm D intern. Recipient of Best Poster Award- PharmD category, UF, CoP Research showcase 2020
- Satyavardhan Rao Nittu (2019-2020): International Pharm D intern
- Leila Becirevic (UF PharmD 2020-2021)
- Molly Hoffy (UF PharmD 2020-2021)
- Han Tran (UF PharmD 2021-2021)
- Han Tran (UF PharmD- Honors 2022-2023)
- Yeniffer Nunez (UF PharmD 2021-2021)
- Gregory Bailey (UF PharmD 2022- present; ISRP, 2023 Summer)
- Kevin Levin (UF PharmD 2022-present)
- Niloofar Moosavi (UF PharmD Jun2023- Aug 2023)
- Franziska Voigt (PharmD internship Germany: May 2022 -Nov 2022)
- Eva Spin (PharmD internship Netherland: Feb 2023-July 2023)
- Marieke Landwehr (PharmD internship Netherland: May 2023-Nov 2023)

Post-doctoral Fellows

- Dr. Amit K Mitra (2009-2012, University of Minnesota)-Currently Tenure Track Assistant professor- Auburn University, Alabama
- Dr. Yogita Ghodke (2010-2012, University of Minnesota)- Assistant Professor of Medicine, Ichan School of Medicine at Mount Siani
- Dr. Lata Chauan (2012-2016, University of Minnesota: University of Florida)
  Recipient of Best Poster Award- Postdoctoral Research Associate category, UF, CoP Research showcase 2016)-Currently Manager/Senior Scientist at CPL Biologicals US. LLC (Joint venture between Cadila Pharmaceuticals and Novavax)

- Dr. Miyoung Shin (2015-2016: University of Florida)- Currently UC San Diego Health Research Associate
- Dr. Roya Rafee (2016- 2021: University of Florida)
  Recipient of Abstract achievement award, ASH Annual Meeting 2019
  Recipient of Best Poster Award- Post-doc category, UF, CoP Research showcase 2020
- Dr. John Papageorgiou Ioannis (2018-2019: University of Florida)
- Dr. Vivek Shastri (2019-present, University of Florida)
- Dr. Phani Parcha (2021- Present, University of Florida)
- Dr. Mohammed Gbadamosi (Jan 2022- Jun 2022, University of Florida)- Currently Tenure Track Assistant professor- University of Florida

Graduate students

- Taraswi Mitra Ghosh (University of Minnesota: Graduated 2016)
- Neha Bhise (University of Minnesota Graduated 2015; Recipient of Best Poster Award- Graduate Student Category, UF, Cop Research day 2016)
- Bradley Stockard Pharm D (University of Florida, Graduated 2019)
  Recipient of Abstract achievement award, American society of Hematology Annual Meeting 2018
- Abdelrahman Elsayed (University of Florida , Graduated 2021)
  Recipient of Best Poster Award- Graduate Student category, UF, Cop Research day 2017
  2nd in Oral session CoP Research Showcase 2018, 2019
  Recipient of Abstract achievement award, American society of Hematology Annual Meeting 2017- 2019
  Recipient of UFHCC predoctoral award, 2020
  Recipient of Presidential Trainee award, American society of Clinical and Pharmacology and Therapeutics 2019
- Salma Bargal (University of Florida, 2015-2017 Graduated with Masters in 2017); Recipient of Best Poster Award - Graduate Student category, UF, CoP Research day 2018
- Mohammad Gbadamosi (University of Florida, 2017 – present)
  Recipient of Minority Abstract achievement award, ASH Annual Meeting 2019,
  Oral presentation ASH, 2019
  Recipient of UFHCC Symposium best poster award, 2020
  Winner Oral session CoP Research Showcase 2021
- Dr. Richard Marrero (University of Florida, 2020-present)
  Recipient T32 PARADIGM fellowship,
  Recipient of Minority Abstract achievement award, ASH Annual Meeting 2022, 2023,
- Dr. Nam Ngyuen (University of Florida, 2020-present):
  Recipient of Scholar in Training Award, AACR
  Recipient T32 PARADIGM fellowship
  Recipient UFHCC Predoctoral award, AFPE predoctoral Award
- Francisco Marchi (University of Florida, 2021-present)
  Recipient of Minority Abstract achievement award, ASH Annual Meeting 2023,
- Satyavardhan Nittu (University of Florida, 2023-present)
- Naifha Alshemeri (MS. University of Florida, 2023-present)
  Recipient of Presidential Trainee award, American society of Clinical and Pharmacology and Therapeutics 2024
- Abdullah Alhumaid (University of Florida, 2023-present)

Thesis Committee Member

- Lucy Hodge (ECP, Ph.D program, Primary Mentor, Dr. Tracy-University of Minnesota)
- Holly Stessman (MCDB&G graduate program, Primary Mentor, Dr. Van Ness, University of Minnesota)

- Lindsay Almquist (Master's program in Epidemiology, Primary Mentor, Dr. Jian-Min Yuan, University of Minnesota)
- Nihal El Rouby (Primary Mentor, Dr. Julie Johnson- University of Florida)
- Guang Yang (Primary Mentor. Dr. Yan Gong, University of Florida)
- Morgan Reeves (University of Florida 2022-present)
- Christiano Marconi (University of Florida 2022-present)

High School Students mentored through University of Florida SSTP program.

Rachel Goepner – 2015; Ella Singh – 2016

PROFESSIONAL SOCIETY MEMBERSHIPS

International Society for the Study of Xenobiotics (ISSX)
American Association of Cancer Research (AACR)
American Society of Pharmacology and Experimental Therapeutics (ASPET)
American Society of Human Genetics (ASHG)
American Society of Hematology (ASH)
American Society of Clinical Pharmacology and therapeutics (ASCPT)
American Association of Colleges of Pharmacy (AACP)
American Association of Pharmaceutical Scientists (AAPS)
American Society of Clinical Oncologists (ASCO)

SERVICE

NIH: Participated in NIH- Trans NCI Pharmacogenomics working group (PPWG) to develop a agenda to advance pharmacoepidemiology and pharmacogenomics in Cancer (2010).

Service

National:

Mentioned before: Grant Reviewer for various National and International Agencies (see above) .

University of Minnesota

- Education Policy /Peer Review Committee (EPC) 2009-2012: College of Pharmacy
  EPC is a standing committee with the responsibility of reviewing courses and curriculum, respond to any educational policy issues and more recently review recommendation for curriculum revision task force. I have so far been actively involved in course reviews and evaluations as we proceed towards curriculum revision.
- Subcommittee on Strategic Planning for research
- Graduate Admissions Committee Experimental and Clinical Pharmacology (2010-present)
- Director of PUMA-Institute of Personalized Medicine (2011-2014).
- Global Health Education Committee (2012-present), College of Pharmacy
- Moderator Pharm.D. IV Seminar Presentations (PHAR 6182, Jan 15, 2014)

University of Florida

- Graduate Program Coordinator since 2015
- Member College of Pharmacy Research task force 2015
- Judge Oral session 2015 Annual College of Pharmacy Research day
- Grant Reviewer: PROSPER 2016 funding
- Search committee member (2015) - Clinical Assistant/Associate Professor Hem/Onc.
- Search Committee Chair- Research Assistant Professor, Dept. of Med Chem
- Search Committee Member: Chair Department of Pharmacodynamics COP, UF
- Grant Reviewer PROSPER 2018 funding
- Pew scholars initial Application Review (2018)
- Office of Research Opportunity funds grant reviewer (2019-2020)
- University of Florida Genetics Institute: Symposium organizing committee (2019-2020)

- Reviewer Oral session abstract, CoP 2022 Annual Research Showcase.
- Reviewer Poster Session: UFHCC Research symposium Jan 2022
- Search Committee chair (2022, U54- CoP, University of Florida)
- UFHCC program grant reviewer- Molecular Mechanisms of Cancer group (2021-Present).
- University of Florida voting member: Scientific review and monitoring committee (SRMC) since 2018- present
- University of Florida Genetics Institute: Chair Symposium organizing committee (2022-2023)
- K College Academic Advisor (2021- present University of Florida)
- Grant reviewer KL12 academy, also part of mock study section (2021- present).
- Academic Personnel Board (2022- present University of Florida)
- University of Florida Genetics Institute: Symposium organizing committee (2022-2023)
- UFGI T32 executive Committee member 2022- present
- Florida Academic Cancer Center Alliance (FACCA) Retreat planning committee (2022- Present)
- UF-CTSI Precision medicine award grant reviewer (Jan/Feb 2023)
- UF-CTSI KL12 grant reviewer (2022-2023)
- UFHCC Research Symposium Poster Judge (Jan 2023)
- SECIM, Advisory member (2023- present)
- ICBR: Advisory committee (2023- present)
- MD-PhD Program interviewers/admissions
- Co-Program leader UFHCC CTT program

Other Services

- Participation as a Faculty trainer in the trainer for the Pharmacogenomics Education T Program (PharmGenEdT): Bridging the Gap between Science and Practice http://pharmacogenomics.ucsd.edu/.
- Have been serving as Judge for DNA essay day sponsored by American Society of Human Genetics (ASHG) since 2008.
- Presented a seminar to 5th graders on leukemia and introduction to pharmacogenetics.
- Abstract reviewer and session moderator – American Society of Hematology, Annual Meeting held December 2021.
- External Faculty Evaluator for promotion and tenure: Moffit Cancer Center,
- External Faculty Evaluator for promotion and tenure :Texas A&M University 2022
- External Faculty Evaluator for promotion and tenure: University of Michigan, Ann Arbor (2022-23)
- American Society of Hematology, Coordinator Reviewer, Abstract reviewer and session moderator – American Society of Hematology, Annual Meeting held December 2022.
- PGRN global 2023 meeting: Scientific program committee member, Abstract reviewer, session chair (2023).
- PGRN grant reviewer (Jan/Feb 2023)
- American Society of Hematology, Precision Medicine Committee member. (2022- present).
- Co-Mentor UCSF K12 training Program (2022-present)
- AACP: Programing committee member
- AFPE Board of grants reviewer
- FACAA symposium planning committee

ABSTRACTS (Podium and poster presentations)

1. Lamba V, **Kaur J**, Dilawari JB, Kohli KK. Genetic polymorphism of drug metabolizing enzymes in Indian subjects. 64th Annual Meeting, Society of Biological Chemists, India, 1995.
2. Lamba V, **Kaur J**, Dilawari JB, Kohli KK. Occurrence of genetic polymorphism of cytochromeP450

2D6 in Indian population. National Symposium on Cancer Research, Shillong, India,1995.
3. **Lamba JK**, Lamba V, Dilawari JB, Kohli KK. Human genetic polymorphism with respect to hepatic cytochrome P450 2C19 in Indian subjects. 16th Annual convention of Indian Association for Cancer Research, Bhuvneshwar, India, 1995.
4. **Lamba JK**, Dhiman RK, Kohli KK. Deficiency in the metabolism of omeprazole by hepatic CYP2C19 in North Indian subjects. 12th International Symposium on Microsomes and Drug Oxidations, MontPellier, France, 1998.
5. Lamba V, **Lamba JK**, Dhiman RK, Kohli KK. Genetic polymorphism of the hepatic cytochrome P4502C19 and 2D6 in North Indians. 1998 Annual meeting of the American Society for Biochemistry and Molecular Biology and ASBMB Satellite meeting, Washington DC, USA. FASEB J 12(8): A1427, 1998.
6. **Lamba JK**, Dhiman RK, Kohli KK. Genetic polymorphism of the hepatic cytochrome P4502C19 in North Indians. International Congress of Frontiers in Pharmacology in the 21st Century, New Delhi, India, 1999.
7. **Lamba JK**, Zhang J, Schuetz EG. Allelic variants of CYP3A4. Gordon research Conference, Plymouth, New Hampshire, USA, 2001.
8. Zheng HX, Webber S, Zeevi A, Schuetz E, Zhang J, **Lamba J**, Bowman P, Burckart GJ. The impact of pharmacogenomic factors on steroid weaning in pediatric heart transplant patients using logistic regression analysis. European Society of Clinical Pharmacy, Florence Italy, 2002.
9. Givens RC, **Lamba JK**, Schuetz, EG, Stewart PW, Watkins PB. (2002) Correlation of cytochrome P450 3A5 genotype with measures of blood pressure and cardiovascular risk predictors. North American ISSX meeting. Drug Metab Rev 34 suppl. 1:32, 2002.
10. **Lamba JK**, Sun S, Tammur J, Schuetz EG, Allikmets R, Schuetz JD. The MRP4 gene reveals exons that would encode truncated proteins unless spliced out. AACR Meeting, San Francisco, California, USA, 2002.
11. Iacono LC, Zamber CP, **Lamba JK**, Odle ED, Schuetz EG, Stewart CF. Single nucleotide polymorphism genotyping of select genes in topotecan-treated children. American College of Clinical Pharmacy Annual Meeting. Albuquerque, New Mexico. Pharmacotherapy 22(10):1362:242, 2002.
12. Zheng HX, Webber S, E Schuetz, Zeevi A, **Lamba J**, Zhang J, Bowman P, Burckart GJ.Tacrolimus dosing in pediatric heart transplant patients is predicted by cytochrome P4503A5, MDR1 and TNF-α genotypes. American College of Clinical Pharmacology 31st Annual Meeting. San Francisco, California. J Clin Pharmacol 42:1061, 2002.
13. Zheng HX, Webber S, Schuetz E, Zeevi A, **Lamba J**, Zhang J, Bowman P, Burckart GJ. Cytochrome P4503A and TNF-a genotypes are associated with tacrolimus dosing in pediatric heart transplant patients. American Society of Histocompatibility and Immunogenetics, 28thAnnual Meeting, Nashville, Tennessee. Hum Immunol 63:S15, 2002.
14. Schuetz EG, **Lamba J**, Lamba V, Zamber C. Pharmacogenetics in the post-genomic era.North American ISSX meeting. Drug Metab Rev 34(suppl 1):5, 2002.
15. **Lamba J**. Lighting up naked DNA : A real time in vivo transcription assay and other applications of hydrodynamic infusion and whole body imaging. **ORAL PRESENTATION**,4th Annual TMGC Retreat, Nashville, Tennessee, USA, 2003.
16. Anderson PL, **Lamba J**, Schuetz E, Fletcher CV. MDR1 genotypes associated with antiviral dynamics and indinavir (IDV) disposition in HIV-infected patients. **ORAL PRESENTATION**. 4th International Workshop on Clinical Pharmacology of HIV Therapy, Cannes France, 2003.
17. **Lamba J**, Strom S, Venkataramanan R, Watkins, PB and Schuetz, EG. Influence of MDR1 genotype on the CYP3A inductive phenotype. SRDG Meeting, Little Rock, Arkansas, USA,2003.
18. Zheng HX, Webber S, Zeevi A, Schuetz E, Zhang J, **Lamba J**, Bowman P, Burckart GJ.(2003). The impact of pharmacogenomic factors on steroid weaning in pediatric hearttransplant patients using logistic regression analysis. International Society for Heart and Lung Transplantation, Vienna, Austria. J Heart Lung Transpl 22(1):S141, 2003.
19. **Lamba JK**, Sun D, Tammur J, Schuetz EG, Allikmets R, Schuetz JD. The MRP4 gene reveals

nonsense encoding transcripts regulated by nonsense mediated mRNA decay. PharmGKB Meeting. Memphis, Tennessee, USA, 2003.
20. Lamba V, **Lamba JK**, Strom S, Hancock H, Ring B, Wrighton W, Schuetz EG. Gender andpopulation differences in CYP2B6 expression and their relationship to CYP2B6 genotype. PharmGKB Meeting. Memphis, Tennessee, USA, 2003.
21. Zamber CP, **Lamba JK**, Yasuda K, Farnum J, Thummel K, Schuetz JD, Schuetz EG. Natural allelic variants of BCRP and their relationship to BCRP expression in human intestine. PharmGKB Meeting. Memphis, Tennessee, USA, 2003.
22. Zheng HX, Zeevi A, **Lamba J**, McCurry K, Webber S, Ristich J, Dauber J, Iacono A, Grgurich W, Zaldonis D, Zhang J, Burckart. Tacrolimus nephrotoxicity is predicted by MDR1 exon 21 gene polymorphism while dosing is predicted by cytochrome P4503A5 polymorphism in adult lung transplant patients. PharmGKB Meeting. Memphis, Tennessee, USA, 2003.
23. Iacono LC, Zamber CP, **Lamba JK**, Odle ED, Schuetz EG, Stewart CF. Single nucleotidepolymorphism genotyping of select genes in topotecan-treated children. PharmGKB Meeting.Memphis, Tennessee, USA.
24. Zheng HX, Zeevi A, McCurry K, Schuetz E, Webber S, Ristich J, Zhang J, Iacono A, DauberJ, McDade K, Zaldonis D, **Lamba J**, Burckart G. MDR exon26 genotype predicts treatment resistance rejection in lung transplant patients as assessed by logistic regression analysis. American Society of Histocompatibility and Immunogenetics 29th Annual Meeting, Miami. Beach, Florida. Hum Immunol 64:S42, 2003.
25. Zheng HX, Zeevi A, McCurry K, Schuetz E, Webber S, Ristich J, Zhang J, Iacono A, DauberJ, McDade K, Zaldonis D, **Lamba J**, Burckart G. MDR exon26 genotype predicts treatmentresistance rejection in lung transplant patients. American College of Clinical Pharmacology 32nd Annual Meeting, Tampa, Florida. J Clin Pharmacol 43:1036, 2003.
26. Zheng HX, Zeevi A, **Lamba J**, McCurry K, Webber S, Ristich J, Dauber J, Iacono A, Grgurich W, Zaldonis D, Zhang J, Burckart. Tacrolimus nephrotoxicity is predicted by MDR1 exon 21 gene polymorphism while dosing is predicted by cytochrome P4503A5 polymorphism in adult lung transplant patients. American Transplant Congress Washington DC. Transplantation3:S(5)426, 2003.
27. Zheng HX, Webber S, Zeevi A, Schuetz E, Zhang J, **Lamba J**, Bowman P, Burckart GJ. The impact of pharmacogenomic factors on steroid weaning in pediatric heart transplant patients using logistic regression analysis. American College of Clinical Pharmacy, Spring Practice and Research Forum, Palm Springs, California, 2003.
28. Zheng HX, Webber S, Zeevi A, Schuetz E, Zhang J, **Lamba J**, Bowman P, Burckart GJ. The impact of pharmacogenomic factors on steroid weaning in pediatric heart transplant patients using logistic regression analysis. International Society for Heart and Lung Transplantation, Vienna, Austria. J Heart Lung Transplant 22(1):S141, 2003.
29. Zheng HX, Webber S, Zeevi A, Schuetz E, Zhang J, **Lamba J**, Bowman P, Boyle G, Law Y, Miller S, Pigula F, Burckart GJ. Steroid weaning and tacrolimus dosing in pediatric heart transplant patients are related to the MDR1 polymorphism at exons 21 and 26. Canadian Society of Pharmaceutical Sciences, Banff, Alberta, Canada, 2003.
30. **Lamba JK**, Stephans A, Lamba V, Strom S, Schuetz EG. Identification of single nucleotidepolymorphisms (SNPs) in cis-regulatory regions of the pregnane X receptor (NR1I2). 2ndCold Spring Harbor Meeting on Pharmacogenomics, Long Island, New York, 2004.
31. Anderson PL, **Lamba JK**, Schuetz EG, Aquilante C, Fletcher C. MRP-4, MRP-2 and BCRP gene polymorphisms in HIV infected patients: Relationship with ZDV and 3TC-triphosphate concentration and indinavir clearance. Conference of Retroviruses and Opportunistic Infections, 2005.
32. Lamba V, Yasuda K, **Lamba J**, Assem M, Davila J, Strom S, Schuetz E. PXR *(NR1I2)*: Splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators. AAPS PharmForum, Memphis, Tennessee, 2004.
33. **Lamba JK**, Lamba V, Yasuda K, Strom S, Schuetz EG. Splice variants of human CAR in different ethnic groups and human tissues and their functional consequences. PharmGKB 4th Annual Scientific

Meeting, Los Angeles, California, USA, 2004.
34. **Lamba JK**, Lamba V, Strom S, Schuetz JD, Schuetz EG. Novel ABCC4 (MRP4) alternative mRNAs in Caucasian, African American and Hispanic human livers. PharmGKB 4th Annual Scientific Meeting, Los Angeles, California, USA, 2004.
35. Wurster W, Nemes R, **Lamba JK**, Schuetz EG, Blaisdell J, Goldstein JA, Reilly TP, Svensson CK. Bioactivation of sulfamethoxazole (SMX) and dapsone (DDS) in normal human keratinocytes (NHEK). Results in the Formation of Drug-Protein Adducts. Drug Hypersensitivity Conference to be held in Bern, Switzerland, 2004.
36. **Lamba JK**, Lamba V, Yasuda K and Schuetz E. Identification and screening of multiple splice variants of human CAR in different ethnic groups and different tissues. Keystone Symposia, Nuclear Receptors: Orphan Brothers (J7) and Steroid Sisters (J8). Colorado,USA, 2004.
37. Anderson PL, **Lamba J**, Schuetz E, Fletcher CV. CYP3A5 and MDR1 (P-gp) polymorphisms in HIV-infected adults: Associations with Indinavir (IDV) concentrations and antiviral effects. Conference on Retroviruses and Opportunistic Infections, 2004.
38. **Lamba J**, Lamba v, Stephen Strom and Schuetz EG. Association of SNPs in trans factors in CYP3A4 regulation. Pharmacogenetics Research Network (PGRN) meeting; St Louis; December 2005.
39. **Lamba J**, Lamba V, Stephens A, Strom S and Schuetz E. Identification of single nucleotide polymorphisms (SNPs) in cis-regulatory regions in pregnane X receptor (NR1I2). 13th NA ISSX/20th JSSX Meeting, Maui, Hawaii, 2005.
40. Lamba V, **Lamba J**, Strom S and Schuetz E. Ethnic and gender variation in hepatic CYP3A4, MDR1 and HNF4alpha. 13th NA ISSX/20th JSSX Meeting, Maui, Hawaii, 2005.
41. Imaging-Based In Vivo Transcription Studies in Mice. Annual AAPS Meeting; Nashville; November 2005; **ORAL PRESENTATION**.
42. Leggas M, Bunaciu RP, Roberts MJ, Du G, **Lamba J**, Scheffer GL, Stewart CF and Schuetz JD. Immunohistochemical analysis of multidrug resistance associated protein-4 (MRP4) expression in human normal and tumor tissues. 97th Annual AACR meeting, Washington DC,2006.
43. **Lamba JK**, Crews K, Pounds S, Schuetz E, Gandhi V, Plunkett W, Rubnitz J and RibeiroR. Deoxycytidine Kinase Genotype Influences Leukemic Blast Concentration of Cytarabine 5 - Triphosphate in Pediatric AML Patients. Annual Meeting ASH, Atlanta, Dec 7-11, 2007. Blood, 2007, 110:225. **ORAL PRESENTATION.**
44. Ilic K, Hogeland G, Rezk N, White N, **Lamba J**, Lee C, Kashuba AD, Schuetz EG, Lindley CM, Chen ML, Hawke RL. The influence of sex, race/ethnicity and CYP 2**b**6 genotype on bupropion (b)Metabolism. 2008 Annual ASCPT Meeting, Florida Apr 2-5 2008. Published in Clinical Pharmacology and Therapeutics, 83:S81-S81 Suppl1, March 2008.
45. **Lamba JK**, Crews K, Pounds S, Schuetz E, Gandhi V, Plunkett W, Rubnitz J and RibeiroR Pharmacogenetics of deoxycytidine kinase (DCK) and 5'nucleotidase (NT5C2): identificationand characterization of novel genetic variants. Pharmacogenetics Research Network (PGRN)meeting; Nashville; April 2008.
46. **Jatinder Lamba**, Amit Mitra, Kristine Crews, Pounds Stanley, Xueyuan Cao, Varsha Gandhi, William Plunkett, Jeffrey Rubnitz, and Raul Ribeiro Pathway Based Pharmacogenomics of Cytarabine In Pediatric Acute Myeloid Leukemia Annual Meeting ASH, Orlando, Dec 6-9, 2010. **ORAL PRESENTATION. Blood:2010; 116: 294**
47. **Jatinder Lamba**, Kristine Crews, Stanley Pounds, Xueyuan Cao, Sharyn Baker, William Plunkett, Varsha Gandhi, James Downing, Jeffrey Rubnitz and Raul Ribeiro Gene expression Profiling of Acute Myeloid Leukemia Shows Therapeutically Meaningful Patterns of Association with Ara-CTP Pharmacokinetics and Pharmacodynamics. Annual Meeting ASH, San Francisco, Dec 6-9, 2008 **ORAL PRESENTATION. Blood; 112; 215**
48. **Jatinder Lamba**, Kristine Crews, Stanley Pounds, Xueyuan Cao, Sharyn Baker, William Plunkett, Varsha Gandhi, James Downing, Jeffrey Rubnitz and Raul Ribeiro Gene expression profiles predicting ara-C pharmacology in pediatric AML patients. GRC meeting on Nucleotides, Nucleosides and Oligonucleotides, July 2009, Rhode Island. Poster presentation.

49. **Jatinder K**. **Lamba**, Amit Mitra, Kristine Crews, Stanley Pounds, Xueyuan Cao, Varsha Gandhi, William Plunkett, Jeffrey Rubnitz, and Raul C Ribeiro. 5'Nucleotidase (NT5C2) Genotype Influences Leukemic Blast Concentration of Ara-CTP in Pediatric Patients with Acute Myeloid Leukemia. ASH Annual Meeting, Dec 2009, New Orleans, **ORAL PRESENTATION. Blood 2009: 114: 593**
50. **Jatinder K. Lamba**, Kristine Crews, Stanley Pounds, Xueyuan Cao, Varsha Gandhi, William Plunkett, Sharyn D. Baker, Ching-Hon Pui, Dario Campana, James R. Downing, Jeffrey Rubnitz, and Raul C Ribeiro. Gene Expression Patterns Associated with Cytarabine Pharmacology and Outcome in Pediatric Acute Myeloid Leukemia. ASH Annual Meeting, Dec 2009, New Orleans, **ORAL PRESENTATION**. Blood 2009; 114:114
51. K.A Jensen, P. A. Jacobson, L. A. Johnson, M. N. Kirstein, **J. K. Lamba**, K. Klotz. Cytotoxic purine nucleoside analogues bind to A1, A2A and A3 receptors. 2010 Annual ASCPT Meeting. Published in Clinical Pharmacology and Therapeutics, 87:S82-S82 Suppl1, Feb 2010.
52. Amit Mitra, Kristine Crews, Stanley Pounds, Xueyuan Cao, Varsha Gandhi, William Plunkett, Jeffrey Rubnitz, Raul C Ribeiro and **Jatinder K**. **Lamba**. 5'Nucleotidase (NT5C2) Genotype Influences Leukemic Blast Concentration of Ara-CTP in Pediatric Patients with Acute Myeloid Leukemia. ISSX meeting on Genetic polymorphisms in drug disposition, Indianapolis, April 11-13, 2010.
53. Jennifer McCormack, and **Jatinder Lamba**. Triptolide exerts a cytotoxic effect on human acute myeloid leukemia cell lines. Pediatric Research, Education and Scholarship Symposium, University of Minnesota, April 23, 2010
54. **JK Lamba**, L Mortland, AK Mitra, RB Walter, J Pollard, TA Alonzo, RB Gerbing, S Meshinchi (2011) Clinical significance of CD33 non-synonymous single nucleotide polymorphisms (SNPs) in pediatric patients with Acute Myeloid Leukemia treated with Gemtuzumab Ozogamicin-containing chemotherapy. Abstract. 53rd ASH Annual Meeting and Exposition. December 10-13, 2011, San Diego, CA: Blood: 2011: 118:3489
55. Amit K Mitra**,** Kristine Crews, Christine Hartford, Stanley Pounds, Xueyuan Cao, Jeffrey Rubnitz, Raul Ribeiro, M. Eileen Dolan, and Jatinder K Lamba (2011) Identification and functional genomic analysis of genetic variants of NT5C2. Abstract. Masonic Cancer Center Research Symposium. May 18, 2011**,** Great Hall, Coffman Memorial Union**,** University of Minnesota, MN.
56. Lauren Wigen, Amit K. Mitra, **Jatinder Lamba** Functional analysis of regulatory SNPs in the hENT1 gene (2011) Undergraduate symposium, University of Minnesota, April 13, 2011, Great Hall, Coffman Memorial Union**,** University of Minnesota, MN.
57. Amit K Mitra, Kristine Crews, Christine Hartford, Stanley Pounds, Xueyuan Cao, Jeffrey Rubnitz, Raul Ribeiro, M. Eileen Dolan, and **Jatinder K Lamba** (2011) Identification and functional genomic analysis of genetic variants of NT5C2. Abstract. Rho Chi ResearchSymposium. March 22, 2011, Mayo Auditorium, University of Minnesota, MN.(won BEST Post-Doc Poster Award)
58. Amit K Mitra, Amit Khatri, Mark N Kirstein, **Jatinder K Lamba** (2011) Pathway-based pharmacogenomics of Gemcitabine pharmacokinetics in patients with solid tumors, Abstract, Rho Chi Research Symposium. March 22, 2011, Mayo Auditorium, University of Minnesota, MN.
59. Amit K Mitra, Amit Khatri, Mark N Kirstein, **Jatinder K Lamba** (2011) Pathway-based pharmacogenomics of Gemcitabine pharmacokinetics in patients with solid tumors, Abstract, 112th ASCPT Annual Meeting 2011, March 2-5, 2011, Dallas, TX.
60. Mortland L and **Lamba J**. Pharmacogenomics of Gemtuzumab Ozogamicin. April 2011, 25th Annual Pediatric Research Education and Scholarship Symposium. University of Minnesota. Podium Presentation.
61. Amit Mitra, Kristine Crews, Pounds Stanley, Xueyuan Cao, Varsha Gandhi, William Plunkett, Jeffrey Rubnitz, Raul Ribeiro and **Jatinder Lamba**, Association of XRCC1 SNPs with clinical response in AML patients. 2012 Annual AACR meeting.
62. Vishal Lamba, Yogita Ghodke, Weihua Guan, Timothy S. Tracy, Jatinder K. Lamba, A Screen for regulatory micrornas reveals a potential role for mir34a in regulating hepatic drug metabolism 18th North American Regional ISSX Meeting October 14-18, 2012 Dallas TX.Drug Metabolism Reviews, 2012; 44(S1): 87

63. Jatinder Lamba **ORAL PRESENTATION (Plenary session 3 speaker)**: Regulatory polymorphism in drug metabolism. 18th North American Regional ISSX Meeting October 14-18, 2012 Dallas TX.
64. Yogita Ghodke, Angela K Birnbaum, Susan E Marino ; Ghada Ahmed, James C Cloyd, Rory P Remmel, Ilo E Leppik, Jatinder K Lamba. Association of carbamazepine metabolism pathway gene polymorphisms pharmacokinetics in patients with epilepsy18th North American Regional ISSX Meeting October 14-18, 2012 Dallas TX. Drug Metabolism Reviews, 2012; 44(S1): 128
65. Michael J Burke, **Jatinder Lamba**, Brenda Weigel, Veronika Bachanova, Michael R. Verneris, and Jeffrey S. Miller A Phase II Trial of Decitabine and Vorinostat in Combination with Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia ASH Annual Meeting, 2012. Dec8-11. Atlanta, Blood (ASH Annual Meeting Abstracts), Blood 2012; 120: 4307.
66. **Jatinder K. Lamba**, Stanley Pounds, Xueyuan Cao, Kristine Crews, Dario Campana, James R. Downing, Raul Ribeiro, and Jeffrey Rubnitz Cytarabine-Induced Gene Expression Signatures in AML Patients and Its Association with Clinical Outcome. ASH Annual Meeting Dec 8-11. Atlanta; Blood (ASH Annual Meeting Abstracts), Blood 2012; **120**: 2470.
67. **Jatinder Kaur Lamba**, Stanley Pounds, Xueyuan Cao, Kristine Radomski Crews, Susana Raimondi, Dario Campana, Sharyn D. Baker, Raul Correa Ribeiro, Jeffrey E. Rubnitz. Genetic variations in cytarabine pathway genes as determinants of outcome in acute myeloid leukemia. **ORAL PRESENTATION**. 2013 ASCO Annual Meeting, June 2013,Chicago.
68. **Jatinder K. lamba**, Tanya Feldberg, Taraswi Mitra Ghosh, Neha Bhise, Brooke Fridley. Genome-wide association analysis identified genetic markers associated with triptolide cellular sensitivity using HapMap LCLs as model system. AACR annual meeting, April 6-10, 2013 Chicago.
69. Neha S. Bhise, **Jatinder K. Lamba**, Role of tumor hypoxia in mediating cellular resistance to Gemcitabine and Cytarabine AACR annual meeting April 6-10, 2013 Chicago.
70. Jatinder Lamba: Pharmacogenomics of AML: a road towards personalized Medicine. **ORAL PRESENTATION.** International Conference on Functional and Comparative Genomics & Pharmacogenomics, Track 6: Pharmacogenomics, Nov 2013 Chicago.
71. Brooke Fridley, Feldberg Tanya, Taraswi Mitra Ghosh, Neha Bhise, and **Jatinder Lamba** CFLAR Genetic Variant Resulting In Alternate Splicing Determines Isoform Specific Production Of H-Cflar Protein and Is Predictive Of Cellular Cytoxicity Of Triptolide In Hapmap Lymphoblast and AML Cell Lines. Annual ASH meeting, New Orleans, LA, Dec 2013; *Blood 2013 122:1287*
72. Bachnova, V, Shanley RA, Burns Linda, Chauhan L and **Lamba JK**. Single Nucleotide Polymorphism in the Cytochrome p450 Gene Positively Impacts Survival Post Cyclophosphamide Conditioning in Autologous Transplants for Lymphoma. **ORAL PRESENATION** 2014 BMT Tandem Meetings. February 2014. Dallas. Texas.
73. **Jatinder Lamba,** Lata Chauhan, Christophe Echeverri, Kerstin Korn, Kartini, Kochar, Xueyuan Cao, and Stanley Pounds High-Throughput, High-Content siRNA/Drug Modifier Screen for Validation of Transcriptional Profiles Predictive of Cytarabine Response in AML. POSTER presentation 2014 Annual ASH meeting Dec 2014- San Francisco, CA; *Blood 24 (21); 2015; 3615*
74. Neha Bhise, Vishal Lamba, **Jatinder K Lamba**. MicroRNA Expression And Drug-Induced Changes in Gene Expression Correlate With Ara-C Chemosensitivity in AML Cell lines. POSTER presentation 2014 Annual ASH meeting Dec 2014- San Francisco, CA. *Blood 24 (21); 2015; 3623*
75. Lata Chauhan, Brooke L. Fridley, Alice Wang, **Jatinder Kaur Lamba**. Identification of markers predictive of phosphoramide mustard (PM) cellular sensitivity in lymphoblast cell lines. Poster presentation 2015 Annual AACR meeting April 2015- Philadelphia, US.
76. Chauhan, Lata, Jenkins, Gregory, Bhise, Neha, Feldberg, Tanya, Ghosh, Taraswi, Fridley, Brooke, **Lamba, Jatinder**. Genome-Wide Association Analysis Identified CFLAR and Splicing SNP in It Predictive of Triptolide Chemo-Sensitivity in Hapmap LCLs. Annual AAPS (American Association of Pharmaceutical Scientists) meeting, Orlando Oct 25-29, 2015.
77. Bhise, Neha, Lamba, Vishal, Cao, Xueyuan, Pounds, Stanley, **Lamba, Jatinder.** Expression of MicroRNAs Predict Response to Cytarabine in Acute Myeloid Leukemia. Annual AAPS (American Association of Pharmaceutical Scientists) meeting, Orlando Oct 25-29, 2015.

78. Stanley Pounds, Xueyuan Cao, Susana Raimondi, James Downing, Raul Correa Ribeiro, Jeffrey E. Rubnitz, **Jatinder Kaur Lamba**. The methylome of pediatric acute myeloid leukemia. Poster session and poster discussion session: 2015 Annual ASCO meeting May 29-Jun2, 2015, Chicago IL. *Journal of Clinical Oncology, 33(15_supple), May 18, 2015;* 10027.
79. **Jatinder K Lamba,** Stanley Pounds*, Xueyuan Cao, Susana C. Raimondi, PhD, James R. Downing, Raul C Ribeiro, and Jeffrey Rubnitz. Methylation of DNMT3B Strongly Associates with the Methylome, Cytogenetic Risk Groups, and Prognosis of Pediatric Acute Myeloid Leukemia. 2015 American Society of Hematology Annual Meeting, Orlando Dec 5-8 2015; Blood 2015;126;2434
80. Lata Chauhan, Emilie J Bergsma, and **Jatinder K Lamba.** Cflar Splicing SNP As Predictor of Chemo-Sensitivity to Anticancer Drugs. 2015 American Society of Hematology Annual Meeting, Orlando Dec 5-8 2015.Blood 2015; 126;2056
81. **Jatinder K Lamba**, Lata Chauhan, Richard Aplenc, Maggie Skrypek, Jessica Pollard, Todd A. Alonzo, Y-C Wang, Irwin D. Bernstein, Alan S. Gamis and Soheil Meshinchi. Genetic Variations in Calicheamicin Pathway Genes Are Predictors of Gemtuzumab Ozogamicin Response in AML Patients: Results from COG-AAML0531 Study. 2015 American Society of Hematology Annual Meeting, Orlando Dec 05-08 2015.Blood 2015;126;1260
82. Sally Kassem, Emilie J. Bergsma, **Jatinder K. Lamba**. SNPs as Predictors of Chemo-sensitivity to Cytarabine. 29th Annual Research Showcase, College of Pharmacy, University of Florida, Jan 22, 2016., BEST POSTER AWARD: PharmD Student Category
83. Bhise, Neha, Lamba, Vishal, Cao, Xueyuan, Pounds, Stanley, **Lamba, Jatinder.** Expression of MicroRNAs Predict Response to Cytarabine in Acute Myeloid Leukemia. University of Florida College of Pharmacy Research Showcase. Jan 2016, BEST POSTER AWARD- Graduate Student Category.
84. Emilie J. Bergsma, Lata Chauhan, Miyoung Shin, Jatinder K. Lamba. CFLAR Splicing SNP as Predictor of Chemo-sensitivity to Anticancer Drugs. 29th Annual Research Showcase, College of Pharmacy, University of Florida, Jan 22, 2016.
85. Bradley Stockard, Elizabeth Dhummakupt, Timothy Garrett, and Jatinder K Lamba. Evaluation of Metabolic Alteration Based on FLT3 Status in Pediatric Acute Myeloid Leukemia Patients by Serum Metabolomics. 29th Annual Research Showcase, College of Pharmacy, University of Florida, Jan 22, 2016.
86. Shin M, Chauhan L, Cao X, Crews K, Pounds S, Lamba JK. Identification of Cytarabine Response Genes in Acute Myeloid Leukemia. 29th Annual Research Showcase, College of Pharmacy, University of Florida, Jan 22, 2016.
87. Lata Chauhan, Richard Aplenc, Maggie Skrypek, Jessica Pollard, Todd A. Alonzo, Y-C Wang, Irwin D. Bernstein, Alan S. Gamis, Soheil Meshinchi, and **Jatinder K Lamba**. CD33 SNPs as markers for identifying patients likely to benefit from gemtuzumab, ozagomicin-a report from the Children's Oncology Group. 29th Annual Research Showcase, College of Pharmacy, University of Florida, Jan 22, 2016. BEST POSTER AWARD- Postdoc Fellow Student Category
88. Jatinder Lamba Speaker and Session chair: Integrated Genomics and epigenomics in pediatric AML. Genomics in Oncology. 21st International Symposium on Microsomes and Drug Oxidation, Davis, California, Oct 2-6 2016.
89. **Jatinder K Lamba**, Lata Chauhan, Michael R. Loken, Jessica Pollard, Yi-Cheng Wang, Ries E Rhonda Richard Aplenc, Betsy A. Hirsch, Susana C. Raimondi, Roland B. Walter, Irwin D. Bernstein, Alan S. Gamis, Todd A. Alonzo, and Soheil Meshinchi, Splicing Polymorphism Is a Strong Predictor of Therapeutic Efficacy of Gemtuzumab Ozogamicin in De Novo AML: Report from COG-AAML0531 Study. 2016 American Society of Hematology Annual Meeting, San Diego Dec 2-6 2016. Blood 2016;128;2743
90. Bradley Stockard, Joy D Guingab, Neha Sanjeev Bhise, *Timothy Garrett and **Jatinder K Lamba**, Cellular Metabolomic Profiling in AML Cell Lines Is Linked to Differences in in Vitro Cytarabine Chemosensitivity. American Society of Hematology Annual Meeting, San Diego Dec 2-6 2016. Blood 2016;128;3954

91. Bradley Stockard, Timothy Garrett, Soheil Meshinchi, and **Jatinder K Lamba**. Metabolomic Profiling Defines Distinct Metabolic Signature Associated with FLT3/ITD AML. American Society of Hematology Annual Meeting, San Diego Dec 2-6 2016. Blood 2016;128;1692.
92. **Jatinder Lamba** Speaker, Session chair and Meeting Organizer: Integrated Genomics and epigenomics in pediatric AML. 9th International conference on Genomics and PharmacoGenomics, Jun 15-16, 2017, London UK.
93. Bradley Stockard, Joy Guingab, Timothy Garrett, Stanley Pounds, Jeffrey E Rubnitz and **Jatinder Lamba**. Global and Targeted Metabolic Profiling Identifies Metabolic Markers for FLT3-ITD in Pediatric AML Patients. American Society of Hematology 2017 Annual Meeting, Atlanta, GA Dec 6-9 2017. Blood 2017 130:5105;
94. **Jatinder Lamba**, Lata Chauhan, Miyoung Shin, Michael R. Loken, Jessica A. Pollard, Jim Wang, Richard Aplenc, Betsy A Hirsch, Susana C. Raimondi, Roland B. Walter, Irwin D. Bernstein, Alan S Gamis, Todd A Alonzo and Soheil Meshinchi CD33-Single Nucleotide Polymorphism (CD33-SNP) Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: Report from Children's Oncology Group AAML0531 Trial. American Society of Hematology 2017 Annual Meeting, Atlanta, GA Dec 6-9 2017.Blood 2017 130:3826.
95. Abdelrahman Elsayed, Kristine R Crews, Xueyuan Cao, Jeffrey E Rubnitz, Stanley Pounds and **Jatinder Lamba**. Risk Score Generated from Ara-C Metabolic Pathway Predicts Leukemic Cell Intracellular Ara-CTP Levels in AML-97 Pediatric Patients. American Society of Hematology 2017 Annual Meeting, Atlanta, GA Dec 6-9 2017. Blood 2017 130:2666 Received Abstract Achievement award.
96. Katherine Tarlock, **Jatinder Lamba** and Soheil Meshinchi CD33 DE2 Transcript Variant Encoded By Splicing Polymorphism Is Devoid of Antibody Binding Site and Lacks Response to CD33 Directed Antibody Drug Conjugates. American Society of Hematology 2017 Annual Meeting, Atlanta, GA Dec 6-9 2017.Blood 2017 130:2661;
97. Lata Chauhan, Todd A Alonzo, Jim Wang, Michael R. Loken, Jessica A. Pollard, Richard Aplenc, Susana C. Raimondi, Roland B. Walter, Betsy A Hirsch, Irwin D. Bernstein, Alan S Gamis, Soheil Meshinchi and **Jatinder Lamba**. Drug Transporter ABCB1 SNP Predicts Outcome in Patients with Acute Myeloid Leukemia Treated with Gemtuzumab Ozagamicin: A Report from Children's Oncology Group AAML0531 Trial. American Society of Hematology 2017 Annual Meeting, Atlanta, GA Dec 6-9 2017. Blood 2017 130:2526
98. Abdelrahman Elsayed and **Jatinder Lamba** Association between Gene Expression Levels of Candidate Cytarabine Pathway and Treatment Outcome Using Publicly Available Data from Target Project. American Society of Hematology 2017 Annual Meeting, Atlanta, GA Dec 6-9 2017. Blood 2017 130:1400;
99. Salma Bargal, Roya Rafiee, Kristine R Crews, Xueyuan Cao, Jeffrey E Rubnitz, Stanley Pounds and **Jatinder Lamba.** Genome-Wide Association Study (GWAS) Identifies SNPs in *GPR56* and *IGF1R* Predictive of Leukemic Cell *In Vitro* cytarabine Sensitivity in Pediatric AML. American Society of Hematology 2017 Annual Meeting, Atlanta, GA Dec 6-9 2017.Blood 2017 130:1426
100. Stockard, B., Guingab, J., Garrett, T., Pettuci, C., Pounds S., Rubnitz, J., **Lamba, J.** "Global and Targeted Metabolic Profiling Identifies Metabolic Markers for FLT3-ITD in Pediatric AML Patients." UFHCC Research Day. November 2017.
101. Abdelrahman Elsayed and **Jatinder Lamba.** "Association Between Gene Expression Levels of Candidate Cytarabine Pathway and Treatment Outcome Using publicly Available Data From TARGET Project". University of Florida Cancer Center Research Day. November 2017
102. Stockard, B., Guingab, J., Garrett, T., Pettuci, C., Pounds S., Rubnitz, J., **Lamba, J.** "Global and Targeted Metabolic Profiling Identifies Metabolic Markers for FLT3-ITD in Pediatric AML Patients." COP Research Showcase Feb 2018.
103. Elsayed A, Cao X, Crews K, Gandhi V, Plunkett W, Rubnitz J, Ribeiro R, Pounds S and **Lamba JK** Cytarabine Metabolic Pathway SNP Risk Score Predicts Leukemic Cell Intracellular Ara-CTP Levels

in Pediatric AML Patients. ORAL PRESENTATION University of Florida College of Pharmacy Research Showcase. February 2018
104. Salma A. Bargal, Roya Rafiee, Kristine R Crews, Xueyuan Cao, Jeffrey E Rubnitz, Stanley Pounds and **Jatinder K Lamba** GWAS for the Identification of Genetic Variants Predictive of Cytarabine *In Vitro* Sensitivity in Pediatric AML. University of Florida College of Pharmacy Research Showcase. February 2018, BEST POSTER AWARD
105. Rafiee R, Shin, M, Chauhan, L, Stockard B , Cao,X, Crews,K, Pounds S **, Lamba JK** Identification of Predictive Markers of Outcome Using Integrated Gene Expression Analysis in Pediatric. University of Florida College of Pharmacy Research Showcase. February 2018, BEST POSTER AWARD
106. Abdelrahman Elsayed, Huiyun Wu, Xueyuan Cao, Susana Raimondi, James Downing, Raul Ribeiro, Tanja Gruber, Jeffrey Rubnitz, Stanley Pounds, **Jatinder K Lamba**. Pediatric LSC3 (pLSC3) Score Derived from DNMT3B-CD34-GPR56 as a Prognostic Tool to Predict AML Patient Outcome: Results from Two Independent Pediatric AML Cohorts.American Society of Hematology 2018 Annual Meeting, San Diego, CA Dec 1-4 2018. ORAL presentation , Blood
107. Abdelrahman Elsayed and **Jatinder K Lamba** Integrated Genome Wide Association Study (GWAS) Identifies SNPs Associated with Outcome in Pediatric AML. American Society of Hematology 2018 Annual Meeting, San Diego, CA Dec 1-4 2018. Abstract Achievement Award
108. Roya Rafiee, Soheil Meshinchi and **Jatinder K Lamba** ABCB1 rs1045642 C>T change is associated with AML cell line sensitivity to calicheamicin. American Society of Hematology 2018 Annual Meeting, San Diego, CA Dec 1-4. 2018
109. Bradley Stockard, Joy Guingab, Timothy Garrett, Stanley Pounds, Jeffrey Rubnitz, **Jatinder K Lamba**. Metabolomics Profiling Reveals Markers for Chemosensitivity and Clinical Outcomes in Pediatric AML Patients. American Society of Hematology 2018 Annual Meeting, San Diego, CA Dec 1-4 2018. Abstract Achievement Award
110. Laura Pardo, Lisa Eidenschink Brodersen, **Jatinder Lamba**, Todd Alonzo, Jim Wang, Dana Paine, Alan S. Gamis, E. Anders Kolb, Jessica Pollard, Richard Aplenc, Soheil Meshinchi, and Michael R Loken. Enhancement of eligibility guidelines for Gemtuzumab Ozogamicin therapy for childhood acute myeloid leukemia: a report from Children's Oncology Group Protocol AAML0531. American Society of Hematology 2018 Annual Meeting, San Diego, CA Dec 1-4 2018
111. Mohammed Gbadamosi, Tiffany A. Hylkema, Soheil Meshinchi, and Jatinder K Lamba. Novel CD33 Antibodies Unravel Localization, Biology, and Therapeutic Implications of CD33 Isoforms. American Society of Hematology 2019 Annual Meeting, Orlando, FL, Dec 7-10 2019. Minority Abstract Achievement Award
112. Abdelrahman H. Elsayed, , Huiyun Wu, Xueyuan Cao, Susana C. Raimondi, James R. Downing, Raul Ribeiro, Tanja A. Gruber, Rhonda E. Ries, Soheil Meshinchi, Jeffrey Rubnitz, Stanley Pounds, and Jatinder K Lamba, A 5-Gene Ara-C, Daunorubicin and Etoposide (ADE) Drug Response Score As a Prognostic Tool to Predict AML Treatment Outcome. American Society of Hematology 2019 Annual Meeting, Orlando, FL, Dec 7-10 2019. Abstract Achievement Award
113. Roya Rafiee, Amin Sobh, Abdelrahman H. Elsayed, Abderrahmane Tagmount, Chris D Vulpe, MD, and Jatinder K Lamba, Genome-Scale CRISPR-Cas9 Synthetic Lethal Screening of AML Cell Line Identified Functional Modulators of Etoposide Resistance Predictive of Clinical Outcome in AML Patients. American Society of Hematology 2019 Annual Meeting, Orlando, FL, Dec 7-10 2019. Abstract Achievement Award
114. Mohammed Gbadamosi, Abdelrahman H. Elsayed, Rhonda E. Ries, Soheil Meshinchi, and Jatinder K Lamba, Preliminary Lasso Regression Analysis Identifies DNA-Damage Gene Expression Signature Predictive of Clinical Outcomes in Patients Using Gemtuzumab Ozogamicin. American Society of Hematology 2019 Annual Meeting, Orlando, FL, Dec 7-10 2019.
115. Roya Rafiee, Amin Sobh, Abdelrahman H. Elsayed, Abderrahmane Tagmount, Chris D Vulpe, MD, and Jatinder K Lamba, Genome-Scale CRISPR-Cas9 Synthetic Lethal Screening of AML Cell Line Identified Functional Modulators of Etoposide Resistance Predictive of Clinical Outcome in AML

Patients. UF College of Pharmacy, , 33rd Annual research showcase, Feb2020. Best Poster award. Post-doctoral category

116. Mohammed Gbadamosi, Tiffany A. Hylkema, Soheil Meshinchi, and Jatinder K Lamba. Novel CD33 Antibodies Unravel Localization, Biology, and Therapeutic Implications of CD33 Isoforms. UF College of Pharmacy, 33rd Annual research showcase, Feb2020. Selection and winner of Oral competition Graduate student

117. Abdelrahman H. Elsayed, Huiyun Wu, Xueyuan Cao, Susana C. Raimondi, James R. Downing, Raul Ribeiro, Tanja A. Gruber, Rhonda E. Ries, Soheil Meshinchi, Jeffrey Rubnitz, Stanley Pounds, and Jatinder K Lamba, A 5-Gene Ara-C, Daunorubicin and Etoposide (ADE) Drug Response Score As a Prognostic Tool to Predict AML Treatment Outcome. UF College of Pharmacy, , 33rd Annual research showcase, Feb2020

118. Akhila Dadwai, Abdelrahman Elsayed and Jatinder K Lamba Single Nucleotide polymorphisms in genes of Prognostic significance in AML. UF College of Pharmacy, 33rd Annual research showcase, Feb2020 Best Poster award. PharmD student category.

119. Satyavardhan Rao Nittu, Abdelrahman Elsayed and Jatinder K Lamba. Transcriptomic approaches to enhance treatment in AML. UF College of Pharmacy, 33rd Annual research showcase, Feb2020

120. Abdelrahman H Elsayed, Xueyuan Cao, Jeffrey E Rubnitz, Raul C Ribeiro, Stanley B Pounds, and Jatinder K Lamba, Ara-C SNP Score as a Predictive Tool of AML Treatment Outcome. ASCPT, 2020. Presidential Trainee Award.

121. Roya Rafiee, Amin Sobh, Abdelrahman H. Elsayed, Abderrahmane Tagmount, Chris D Vulpe, MD, and Jatinder K Lamba, Genome-scale CRISPR-Cas9 synthetic lethal screening of myeloid cell line identifies CBFA2T3, DHX8, and NOC4L as functional modulators of daunorubicin resistance. Accepted for poster presentation at 2020 Annual AACR meeting, presented virtually.

122. Vivek Shastri, Lata Chauhan, Todd A. Alonzo, Yi-Cheng Wang, Richard Aplenc, Betsy A. Hirsch, Alan S. Gamis, Soheil Meshinchi, and Jatinder K. Lamba, The DDB2 intronic variation rs830083 is a strong predictor of gemtuzumab ozogamicin response in AML patients: A calicheamicin pathway-directed analysis from the COG-AAML0531 trial. Accepted for poster presentation at 2020. Annual AACR meeting presented virtually.

123. Abdelrahman H. Elsayed, Xueyuan Cao, Jeffrey E Rubnitz, Raul C Ribeiro, Stanley B Pounds, and Jatinder K Lamba. “Ara-C SNP Score as a Predictive Tool of AML Treatment Outcome”. 2020 American Society for Clinical Pharmacology and Therapeutics (ASCPT) annual meeting; ASCPT Presidential Trainee Award.

124. Nguyen NK, Elsayed AH, Meshinchi S, Lamba JK. An Ara-C, Daunorubicin, and Etoposide microRNA (ADEmiR) Score As a Prognostic Tool to Predict AML Treatment Outcomes. 2020 American Society of Hematology (ASH) Virtual Conference & UFHCC Cancer Research Showcase;ASH Abstract Achievement Award.

125. Trisha Larkin, Abdelrahman H Elsayed, Roya Rafiee, Natasha Emanuel, Beate Greer, Biljana N. Horn, and Jatinder K Lamba. Identification of Pharmacogenomic Single Nucleotide Polymorphism Variants As Contributors to Toxicity Phenotype in the Treatment of Acute Childhood Leukemia. 2020 American Society of Hematology (ASH) Virtual Conference

126. Emanuel N, Larkin T, Elsayed A, Rafiee R, Horn B, Lamba JK. "Using Pharmacogenomics Testing to Optimize Care in Children with Acute Lymphoblastic Leukemia", 2020 Florida Society of Health-System Pharmacists (FSHP) 54th Annual Conference

127. Gbadamosi M, Elsayed AH, Nguyen N, Shastri V, de Jesus A, Olabige O, Ries R, Meshinchi S, Lamba JK. The CIDDR gene expression signature predicts response to gemtuzumab ozogamicin. 34th Annual UF College of Pharmacy Research Showcase, April 2021; Oral Presentation; Winner of Oral Presentation Competition in the Senior Clinical Sciences section

128. Shastri VM, Chauhan L, Alonzo TA, Wang Y-C, Aplenc R, Hirsch B, Gamis A, Meshninchi S and Lamba JK. DDR-4-SNP score predicts GO response in AML patients: A pathway-directed analysis.

Poster presentation at: 34th Annual Research Showcase, College of Pharmacy, University of Florida, April 2021; Gainesville, FL. UF College of Pharmacy 34rd Annual Research Showcase.
129. Marrero RJ, Elsayed A, Nguyen NK, Cao X, Wu H, Raimondi S, Riberio R, Rubnitz J, Pounds S and Lamba JK. Association of Genetic Polymorphisms in SAMHD1 Gene on Clinical Outcomes in AML. 34th Annual Research Showcase, College of Pharmacy, University of Florida, April 2021; Gainesville, FL
130. Emanuel N, Larkin T, Elsayed A, Rafiee, R, Greer B, horn B and Lamba J. Identification of SNPs to optimize the treatment of acute childhood leukemia. 34th Annual Research Showcase, College of Pharmacy, University of Florida, April 2021; Gainesville, FL.
131. Tran H, Becirevic L, Emanuel N, Lofy, M Shastri V, Lamba J. Ara-C SNP score to personalize cytarabine dosing: a retrospective study. 34th Annual Research Showcase, College of Pharmacy, University of Florida, April 2021; Gainesville, FL.
132. Cuevas M, Kelly J, Lamba J, Gene associated asparaginase hypersensitivity in pediatric ALL. 34th Annual Research Showcase, College of Pharmacy, University of Florida, April 2021; Gainesville, FL.
133. Harrison B, Callender R, Lamba J, Ramos C, Impact of gene associated methotrexate toxicity in acute lymphoblastic leukemia. 34th Annual Research Showcase, College of Pharmacy, University of Florida, April 2021; Gainesville, FL.
134. Nguyen NK, Wu H, Ping J, Rubnitz J, Pounds S, Lamba JK. Leukemic Cell Proteomic Profiling in Pediatric AML A Pilot Study. 2021 American Association for Cancer Research (AACR) Virtual Conference. [Poster #2535] AACR Scholar-in-Training Award. April 2021 Virtual.
135. Marrero RJ, Elsayed A, Cao X, Wu H, Wang L, Ribeiro, R, Rubnitz J, Pounds S, Lamba JK. Impact of SAMHD1 on Cytarabine in Pediatric AML Patients. University of Florida Health Cancer Center Virtual Symposium, December 7, 2021 (**Best Poster Award -Graduate Student Category Poster Winner**).
136. Shastri VM, Chauhan L, Alonzo TA, Wang Y, Aplenc R, Hirsch B, Gamis A, Meshinchi S, Lamba JK. A Polygenic DNA Damage Repair Pharmacogenomics (DDR_PGx8) Score Predicts GO Response in AML. University of Florida Health Cancer Center Virtual Symposium, December 7, 2021 (**Best Poster Award- Post-Doctoral Poster Category**).
137. Richard J Marrero, Abdelrahman H Elsayed, Xueyuan Cao, Huiyun Wu, Lei Wang, Raul C Ribeiro, Jeffrey E. Rubnitz, Stanley B Pounds, Jatinder K. Lamba Impact of SAMHD1 Pharmacogenetics on Clinical Outcome in Pediatric AML Journal: *Blood* (2021) 138 (Supplement 1): 3429. DOI: https://doi.org/10.1182/blood-2021-147528; American Society of Hematology (ASH) Annual Meeting, December 13, 2021 (**ASH Abstract Achievement Award**).
138. Jennifer Ahmed, Leila Becirevic, Natasha Emanuel, Molly E. Lofy, Hanh Tran, Vivek M. Shastri, Jatinder K. Lamba Pharmacogenomics to Predict Mucositis in Acute Myeloid Leukemia Journal: *Blood* (2021) 138 (Supplement 1): 2373. DOI: https://doi.org/10.1182/blood-2021-154046, American Society of Hematology (ASH) Annual Meeting, Atlanta, USA, December 13, 2021
139. Nguyen NHK, Shastri V, Lu Y, PhD, Winger BA, Long-Boyle J, Horn B, MD, Lamba JK. Pharmacogenomics of Fludarabine in Pediatric HCT Recipients: Preliminary Results Journal: *Blood* (2021) 138 (Supplement 1): 908. DOI: https://doi.org/10.1182/blood-2021-151457. American Society of Hematology (ASH) Annual Meeting 2021 [**Oral Presentation #908]; ASH Abstract Achievement Award;** Atlanta, USA, Dec 13, 2021
140. Vivek M. Shastri, Lata Chauhan, Todd A. Alonzo, Yi-Cheng Wang, Richard Aplenc, Betsy A Hirsch, Alan S. Gamis, Soheil Meshinchi, Jatinder K. Lamba A Polygenic DNA Damage Repair Pharmacogenomics (DDR_PGx8) Score Predicts GO Response in AML. Journal: *Blood* (2021) 138 (Supplement 1): 3456.DOI: https://doi.org/10.1182/blood-2021-153181 American Society of Hematology (ASH) Annual Meeting, Atlanta, USA, December 13, 2021 (**ASH Abstract Achievement Award**).
141. Mohammed O Gbadamosi, Vivek M. Shastri, Soheil Meshinchi, Jatinder K. Lamba The rs35112940 CD33 Polymorphism Reduces CD33 Internalization and Efficacy of CD33-Directed

Gemtuzumab Ozogamicin Journal: *Blood* (2021) 138 (Supplement 1): 2247. DOI: https://doi.org/10.1182/blood-2021-150927, American Society of Hematology (ASH) Annual Meeting, Atlanta, USA, December 13, 2021

142. Reema Kashif, Trisha Larkin, Abdelrahman H Elsayed, Nam H.K. Nguyen, Natasha Emanuel, Vivek M. Shastri, Roya Rafiee, Karna Mangrola, Biljana N. Horn, Jatinder K. Lamba Pharmacogenomic Single Nucleotide Polymorphism (SNP) Variants As Predictors of Toxicity Phenotypes in the Treatment of Acute Childhood Leukemia Journal: *Blood* (2021) 138 (Supplement 1): 3360. DOI: https://doi.org/10.1182/blood-2021-151357 American Society of Hematology (ASH) Annual Meeting, Atlanta, USA, December 13, 2021

143. Vivek M. Shastri, Tiffany A. Hylkema, Mohammed O Gbadamosi, Soheil Meshinchi, Jatinder K. Lamba Unraveling Subcellular Localization of CD33 Splicing Polymorphism Variant Journal: *Blood* (2021) 138 (Supplement 1): 1290.DOI: https://doi.org/10.1182/blood-2021-153432 American Society of Hematology (ASH) Annual Meeting, Atlanta, USA, December 13, 2021

144. Marrero RJ, Elsayed A, Cao X, Wu H, Wang L, Ribeiro, R, Rubnitz J, Pounds S, Lamba JK. Impact of SAMHD1 on Cytarabine in Pediatric AML Patients. Florida Academic Cancer Center Alliance 2022 Retreat, January 18, 2022 (poster).

145. Nguyen NHK, Rafiee R, Tagmount A, Gbadamosi M, Elsayed AH, de Jesus Sosa AK, Sobh A, Loguinov A, Cogle CR, Rubnitz J, Ribeiro R, Downing J, Cao X, Pounds SB, Vulpe CD, and Lamba JK. UF College of Pharmacy 35th Research Showcase[Oral Presentation - Junior Category]; Finalist; Feb 7, 2022, UF-COP

146. Marchi F, Stockard B, Nguyen N, Marrero R, Gbadamosi M, Sckaff F, Shastri V, Parcha P, Ahmed J, Garrett T, Rubnitz J, Pounds S, Lamba JK. A Metabolite Signature Predicts Outcome in Pediatric AML Patients. Feb 7, 2022 University of Florida College of Pharmacy 35th Annual Research Showcase. **Cancer Research category best poster Award**

147. Voigt F, Marrero RJ, Cao X, Ribeiro, R, Rubnitz J, Pounds S, Lamba JK. GWAS to Identify Variants Associated with MRD1 in Children Diagnosed with AML. University of Florida College of Pharmacy 35th Annual Research Showcase February 7, 2022 (poster).

148. Vivek M. Shastri, Lata Chauhan, Todd A. Alonzo, Yi-Cheng Wang, Richard Aplenc, Betsy A Hirsch, Alan S. Gamis, Soheil Meshinchi, Jatinder K. Lamba Polygenic pharmacogenomics score predicts response to gemtuzumab ozogamicin. Department of Pharmacotherapy & Translational Research. University of Florida College of Pharmacy 35th Annual Research Showcase, February 7, 2022 (Oral).

149. Ahmed J, B. Stockard; N. Bhise; J. Cagmat; T. Garrett; J. Lamba Cytarabine-induced metabolome profiling in acute myeloid leukemia cell lines. University of Florida College of Pharmacy 35th Annual Research Showcase February 7, 2022 (poster).

150. Parcha PK, M. Shin; L. Chauhan; X. Cao; K. Crews; S. Pounds; J. Lamba. Integrated gene expression analysis for identifying therapeutic targets in AML. University of Florida College of Pharmacy 35th Annual Research Showcase, February 7, 2022 (poster).

151. Marrero RJ, Elsayed A, Cao X, Wu H, Wang L, Ribeiro, R, Rubnitz J, Pounds S, Lamba JK. Impact of SAMHD1 pharmacogenetics on clinical outcome Pediatric AML. University of Florida College of Pharmacy 35th Annual Research Showcase, February 7, 2022 (poster).

152. Nguyen NHK, Kashif R, Larkin T, Elsayed A, Emanuel N, Shastri V, Rafiee R, Mangrola K, Horn B, Lamba JK. Pharmacogenomic Single Nucleotide Polymorphism (SNP) Scores as A Tool to Predict Toxicity Phenotypes in Treatment of Acute Childhood Leukemia (ALL). American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2022 Annual Meeting [Poster #PT-012**]; ASCPT David J. Goldstein Trainee Award, ASCPT Presidential Trainee Award;** March 8-17, 2022**, Virtual**

153. Shastri VM, Chauhan L, Alonzo TA, Wang Y, Aplenc R, Hirsch B, Gamis A, Meshinchi S, Lamba JK. A Polygenic DNA Damage Repair Pharmacogenomics (DDR_PGx8) Score Predicts GO Response in AML. 2022 American Society for Clinical Pharmacology & Therapeutics Annual Meeting, March 8-17, 2022 (**Presidential Trainee Award**).

154. Marrero RJ, Elsayed A, Cao X, Wu H, Wang L, Ribeiro, R, Rubnitz J, Pounds S, Lamba JK. Impact of SAMHD1 on Cytarabine in Pediatric AML Patients. The National Human Genome Research Institute (NHGRI) Annual Meeting, April 4, 2022 (poster).
155. Richard J. Marrero, Abdelrahman Elsayed, Xueyuan Cao, Susan Raimondi, Ching-Hon Pui, Raul Ribeiro, Jeffrey Rubnitz, Stanley Pounds, and Jatinder K. Lamba. GWAS Identifies Variants Associated with Clinical Outcomes in Pediatric Patients with Newly Diagnosed AML. 2022 University of Florida Genetics Symposium, November 2, 2022 (poster)
156. Jatinder K. Lamba, Richard J Marrero, Abdelrahman H Elsayed, Xueyuan Cao, Huiyun Wu, Hiroto Inaba, Susana C. Raimondi, Ching-Hon Pui, Raul C. Ribeiro, Jeffrey E. Rubnitz, Stanley B. Pounds. Personalization of Induction Therapy for Pediatric AML to Ara-C+Dauno+ Etoposide (ADE) or Clofarabine+Ara-C According to a Polygenic Ara-C SNP Score- ACS10. American Society of Hematology (ASH) Annual Meeting, New Orleans, USA, December, 2022 Journal: Blood Blood (2022) 140 (Supplement 1): 1039–1040. DOI: https://doi.org/10.1182/blood-2022-159657. Oral Session
157. Richard J Marrero, Xueyuan Cao, Huiyun Wu, Hiroto Inaba, Susana C. Raimondi, Ching-Hon Pui, Raul C. Ribeiro, Jeffrey E. Rubnitz, Stanley B. Pounds, Jatinder K. Lamba Genome-Wide Association Study Identifies Variants Associated with Clinical Outcomes in Pediatric Patients with Newly Diagnosed Acute Myeloid Leukemia. American Society of Hematology (ASH) Annual Meeting, New Orleans, USA, December, 2022;Journal:Blood (2022) 140 (Supplement 1): 6295–6296.DOI: https://doi.org/10.1182/blood-2022-159534. Minority ASH Abstract Achievement Award
158. Jatinder K. Lamba, Xueyuan Cao, Huiyun Wu, Hiroto Inaba, Raul C. Ribeiro, Junmin Peng, Tanja A. Gruber, Jeffrey E. Rubnitz, Stanley B. Pounds. Proteomic Analysis Identifies Epigenetic Modifiers and Potential Negative Regulators of Leukemogenesis KMD6A and SETDB1 to be Induced Post In Vivo Decitabine Exposure in Pediatric AML. American Society of Hematology (ASH) Annual Meeting, New Orleans, USA, December, 2022;Journal: Blood (2022) 140 (Supplement 1): 6086–6087.DOI: https://doi.org/10.1182/blood-2022-166671.
159. Phani Krishna Parcha, Xueyuan Cao, Jeffrey E. Rubnitz, Raul C. Ribeiro, Stanley Pounds, Jatinder K. Lamba Integrated Gene Expression Analysis Identifies ETS2 Involved in Oncogene Induced Senescence to be Associated with Poor Outcome in Paediatric AML.American Society of Hematology (ASH) Annual Meeting, New Orleans, USA, December, 2022; Journal: Blood (2022) 140 (Supplement 1): 11781–11782.DOI: https://doi.org/10.1182/blood-2022-163689.
160. Francisco Marchi, Fernando Sckaff, Xueyuan Cao, Raul C. Ribeiro, Jeffrey E. Rubnitz, Stanley B. Pounds, Jatinder K. Lamba. A Cibersortx Signature Predicts Outcome in Pediatric AML Patients. American Society of Hematology (ASH) Annual Meeting, New Orleans, USA, December, 2022; Journal: Blood (2022) 140 (Supplement 1): 3441–3442. DOI: https://doi.org/10.1182/blood-2022-163366. (ASH Abstract Achievement Award)
161. Nam H.K. Nguyen, Abderrahmane Tagmount, Jeffrey E. Rubnitz, Raul C. Ribeiro, Xueyuan Cao, Stanley B. Pounds, Chris D. Vulpe, Jatinder K. Lamba. Genome-Wide CRISPR/Cas9 Screen Identifies AraC-Daunorubicin-Etoposide (ADE) Response Modulators Associated with Clinical Outcomes in Pediatric AML. American Society of Hematology (ASH) Annual Meeting, New Orleans, USA, December, 2022; Journal: *Blood* (2022) 140 (Supplement 1): 5947–5948. DOI: https://doi.org/10.1182/blood-2022-159322
162. Fernando Sckaff, Francisco Marchi, Xueyuan Cao, Raul C. Ribeiro, Jeffrey E. Rubnitz, Stanley B. Pounds, Jatinder K. Lamba; An Epigenetic Signature Predicts Outcome in Pediatric AML Patients. UF Health Cancer Center Research Day Jan 2023. (Undergraduate best poster award).
163. Mohammed Gbadamosi, Neha Bhise, Taraswi Mitra Ghosh, Elizabeth Molchan[2]Oluwaseyi Olabige, Changlin Yang[2] Duane Mitchell, Brooke Fridley, and Jatinder K. Lamba. A Genome-Wide Association Study Using HapMap Cell Lines Reveals Key Modulators of Response to Cyclophosphamide. UF Health Cancer Center Research Day Jan 2023. (Postgraduate best poster award).
164. Nguyen NHK, Tagmount A, Rubnitz J, Ribeiro R, Cao X, Pounds SB, Vulpe CD, Lamba JK. Genome-wide CRISPR/Cas9 Screen Identifies AraC-Daunorubicin-Etoposide (ADE) Response

Modulators Associated with Clinical Outcomes in Pediatric AML. UF Health Cancer Center Research Day Jan 2023 [Oral Presentation]
165. Francisco Marchi, Fernando Sckaff, Xueyuan Cao, Raul C. Ribeiro, Jeffrey E. Rubnitz, Stanley B. Pounds, Jatinder K. Lamba; A Cibersortx Signature Predicts Outcome in Pediatric AML Patients. UF College of Pharmacy 36th Annual Research Showcase. COP Research Showcase Feb 2023 (Basic & Translational Science: Cancer best poster award).
166. Mohammed Gbadamosi, Neha Bhise, Taraswi Mitra Ghosh, Elizabeth Molchan[2]Oluwaseyi Olabige, Changlin Yang[2] Duane Mitchell, Brooke Fridley, and Jatinder K. Lamba. Jatinder K Lamba: Integrated omics analysis identifies modulators of cyclophosphamide response. COP Research Showcase Feb 2023
167. Jihyun Bae, Richard J Marrero, Xueyuan Cao, Huiyun Wu, Hiroto Inaba, Susana C. Raimondi, Ching-Hon Pui, Raul C. Ribeiro, Jeffrey E. Rubnitz, Stanley B. Pounds, Jatinder K. Lamba GWAS identifies genetic variants associated with metabolites in pediatric AML. COP Research Showcase Feb 2023
168. Richard J Marrero, Xueyuan Cao, Huiyun Wu, Hiroto Inaba, Susana C. Raimondi, Ching-Hon Pui, Raul C. Ribeiro, Jeffrey E. Rubnitz, Stanley B. Pounds, Jatinder K. Lamba GWAS identifies SNPs associated with clinical outcome in children with AML. COP Research Showcase Feb 2023
169. Phani Krishna Parcha, Xueyuan Cao, Jeffrey E. Rubnitz, Raul C. Ribeiro, Stanley Pounds, Jatinder K. Lamba Proteomic analysis identifies potential negative regulators of leukemogenesis COP Research Showcase Feb 2023
170. Nam H.K. Nguyen, Abderrahmane Tagmount, Jeffrey E. Rubnitz, Raul C. Ribeiro, Xueyuan Cao, Stanley B. Pounds, Chris D. Vulpe, Jatinder K. Lamba. Genome-Wide CRISPR/Cas9 Screen Identifies AraC-Daunorubicin-Etoposide (ADE) Response Modulators Associated with Clinical Outcomes in Pediatric AML. UF College of Pharmacy Research Showcase: Feb 2023
171. Richard J Marrero, Xueyuan Cao, Huiyun Wu, Hiroto Inaba, Susana C. Raimondi, Ching-Hon Pui, Raul C. Ribeiro, Jeffrey E. Rubnitz, Stanley B. Pounds, Jatinder K. Lamba GWAS to identify variants associated with MRD in pediatric patients with AML. UF College of Pharmacy Research Showcase: Feb 2023. Oral Presentation.
172. Nguyen NHK, Phani KP, Tagmount A, Rubnitz J, Ribeiro R, Cao X, Pounds SB, Vulpe CD, Lamba JK. Genome-wide CRISPR/Cas9 Screen Identifies AraC-Daunorubicin-Etoposide (ADE) Response Modulators Associated with Clinical Outcomes in Pediatric AML. NHGRI Research Training and Career Development Annual Meeting April 2023. Poster Presentation
173. Richard J. Marrero, Abdelrahman Elsayed, Xueyuan Cao, Susan Raimondi, Ching-Hon Pui, Raul Ribeiro, Jeffrey Rubnitz, Stanley Pounds, and Jatinder K. Lamba. Genome-wide Association Study in Children Diagnosed with Acute Myeloid Leukemia. The National Human Genome Research Institute (NHGRI) Annual Meeting, April 2, 2023. Poster Presentation
174. Satyavardhan Rao Nittu, Francisco Marchi, Jatinder K Lamba. Relapse Enriched Gene Expression Signature to Predict Treatment Outcome in Pediatric AML: Pharmacogenomics Research Network (PGRN) Annual Meeting, Memphis, USA, June 12, 2023 PGRN 2023
175. VM. Shastri, L. Chauhan, TA. Alonzo, Y-C. Wang, R. Aplenc, Hirsch, AS. Gamis, S. Meshinchi and JK. Lamba. A polygenic DNA damage repair pharmacogenomics (DDR_PGx7) score predicts response to GO in AML: A calicheamicin pathway-directed analysis from the COG-AAML03P1 and COG-AAML0531 trials. Pharmacogenomics Research Network (PGRN) Annual Meeting, Memphis, USA, June 12, 2023 PGRN 2023
176. Nguyen NHK, Phani KP, Tagmount A, Rubnitz J, Ribeiro R, Cao X, Pounds SB, Vulpe CD, Lamba JK. Genome-wide CRISPR/Cas9 Screen Identifies AraC-Daunorubicin-Etoposide (ADE) Response Modulators Associated with Clinical Outcomes in Pediatric AML. PGRN Annual Scientific Meeting June 2023. Abstract achievement award recipient.
177. Francisco Marchi, Marieke Landwehr, Fernando Sckaff, Xueyuan Cao, Raul C. Ribeiro, Jeffrey E. Rubnitz, Alan S Gamis, E. Anders Kolb, , Richard Aplenc, , Stanley Pounds, Todd A. Alonzo, Soheil Meshinchi, and Jatinder K. Lamba, The Methylome Atlas of Acute Leukemia Enables Novel Clinical

Diagnostic Tool for AML. *Blood* (2023) 142 (Supplement 1): 121 https://doi.org/10.1182/blood-2023-186894 Oral Presentation Abstract achievement award recipient, ASH2023, San Diego, US.

178. Francisco Marchi, Marieke Landwehr, Fernando Sckaff, Xueyuan Cao, Raul C. Ribeiro, Jeffrey E. Rubnitz, Alan S Gamis, E. Anders Kolb, , Richard Aplenc, , Stanley Pounds, Todd A. Alonzo, Soheil Meshinchi, and Jatinder K. LambaA DNA Methylation Signature Predicts Clinical Outcome in Pediatric AML Patients. *Blood* (2023) 142 (Supplement 1):835 https://doi.org/10.1182/blood-2023-186505Oral Presentation Abstract achievement award recipient. ASH2023, San Diego, US.

179. Satyavardhan Rao Nittu, Francisco Marchi, Nam Nguyen, Vivek M. Shastri, Xueyuan Cao, Raul C. Ribeiro, Jeffrey E. Rubnitz, Alan S Gamis, E. Anders Kolb, Richard Aplenc, Jeffery Klco, Stanley Pounds, Todd A. Alonzo, Soheil Meshinchi, Jatinder K. Lamba. Relapse-Enriched Gene Expression Signature of Prognostic Relevance in Pediatric Acute Myeloid Leukemia, ASH 2023, *Blood* (2023) 142 (Supplement 1): 2926 https://doi.org/10.1182/blood-2023-189029 ASH2023, San Diego, US.

180. Richard J Marrero, Vivek M. Shastri, Richard Aplenc, Todd Cooper, Todd A. Alonzo, Alan S Gamis, Jim Wang, Soheil Meshinchi, E. Anders Kolb, Jatinder K. Lamba. ACS10- Cytarabine Pharmacogenomics Score Impacts Survival in Pediatric AML Patients Treated on AAML1031 Trial and Associates with Outcome Differences in Black AML Patients. *Blood* (2023) 142 (Supplement 1): 4314, https://doi.org/10.1182/blood-2023-187515 ASH2023, San Diego, US

181. Nam Nguyen, Phani Krishna Parcha, Abderrahmane Tagmount, Bailey Gregory, Jeffrey E. Rubnitz, Raul C. Ribeiro, Xueyuan Cao, Todd A. Alonzo, Richard Aplenc, Alan S Gamis, Todd Cooper, E. Anders Kolb, Soheil Meshinchi, Stanley Pounds, Christopher Vulpe, Jatinder K. Lamba. Leveraging Custom CRISPR/Cas9 Screens to Identify AraC-Daunorubicin-Etoposide (ADE), Gemtuzumab Ozogamicin (GO), and Bortezomib Response Modulators Association with Clinical Outcomes in Pediatric AML. *Blood* (2023) 142 (Supplement 1):1558, https://doi.org/10.1182/blood-2023-178832 ASH2023, San Diego, US

182. Nam Nguyen, Phani Krishna Parcha, Abderrahmane Tagmount, Bailey Gregory, Xueyuan Cao, Stanley Pounds, Christopher Vulpe, and Jatinder K. Lamba, CRISPR/Cas9 Screen Identifies CPX-351 and 7+3 Regimens Response Modulators with Distinct Sensitive and Resistant Profiles. *Blood* (2023) 142 (Supplement 1): 1412, https://doi.org/10.1182/blood-2023-174281 ASH2023, San Diego, US

183. Richard J Marrero, Deedra Nicolet, Vivek M. Shastri, Krzysztof Mrózek, Christopher J. Walker, William Blum, Bayard L Powell, Jonathan E Kolitz, Joseph O Moore, Geoffrey L Uy, Wendy Stock, Andrew J Carroll, John C. Byrd, Ann-Kathrin Eisfeld, Jatinder K. Lamba. Impact of Cytarabine Pharmacogenomics on Survival of Adolescent and Young Adults with AML and Its Clinical Relevance in Black Patients. *Blood* (2023) 142 (Supplement 1): 2954 https://doi.org/10.1182/blood-2023-187361 ASH2023, San Diego, US

184. Jatinder K. Lamba, Richard J Marrero, Huiyun Wu, Xueyuan Cao, Phani Krishna Parcha, Seth E. Karol, Hiroto Inaba, Dennis John Kuo, Barbara Degar, Kenneth Matthew Heym, Jeffrey Taub, Norman J. Lacayo, Ching-Hon Pui, Raul C. Ribeiro, Stanley Pounds, Jeffrey E. Rubnitz, Intensification of Therapy and Pharmacogenetic Personalization Mitigate Racial Disparities in Pediatric Acute Myeloid Leukemia Outcomes. *Blood* (2023) 142 (Supplement 1): 386, https://doi.org/10.1182/blood-2023-173617 Oral Presentation, ASH2023, San Diego, US

185. Richard J Marrero, Xueyuan Cao, Huiyun Wu, Raul C. Ribeiro, Jeffrey E. Rubnitz, Stanley Pounds, Jatinder K. Lamba. GWAS Identifies Variants Associated with Minimal Residual Disease after Induction I in Pediatric Patients with Newly Diagnosed Acute Myeloid Leukemia. *Blood* (2023) 142 (Supplement 1): 2967, https://doi.org/10.1182/blood-2023-179946 ASH2023, San Diego, US